Parkinson's Disease

Ask OpenScientist

Ask a research question about Parkinson's Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

◈

Mechanistic Hypotheses

Canonical α-Synucleinopathy and Dopaminergic Neurodegeneration Model

canonical_synucleinopathy_dopaminergic_neurodegeneration_model CANONICAL

Misfolded α-synuclein aggregates into oligomers and Lewy bodies, propagates trans-synaptically in a prion-like manner, and induces progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. The resulting striatal dopamine deficiency causes the cardinal motor signs (bradykinesia, rigidity, tremor, postural instability), while broader Lewy pathology in autonomic, brainstem, and cortical regions accounts for the non-motor symptoms (REM-sleep behavior disorder, hyposmia, constipation, cognitive impairment). Pathway evidence implicates impaired autophagy/lysosomal clearance (GBA), mitochondrial dysfunction (PINK1/Parkin), and oxidative stress as upstream amplifiers; loss of dopaminergic feedback to the indirect/direct basal ganglia circuits explains the motor circuit signature.

Retained as CANONICAL. The 2026 falcon hypothesis-search report (kb/hypotheses/Parkinsons_Disease/canonical_synucleinopathy_dopaminergic_neurodegeneration_model; openscientist timed out) confirms misfolded α-synuclein aggregation, Lewy-body formation, and progressive substantia-nigra pars-compacta dopaminergic neuron loss as the central mechanism. Three qualifications: (1) the prion-like cell-to-cell propagation model is well-validated in mouse and primate models (intracerebral PFF injection seeds endogenous aggregates and produces motor deficits), but its rate-limiting role in human sporadic PD remains debated; (2) GBA1 heterozygosity, mitochondrial dysfunction (PINK1/Parkin), impaired autophagy/lysosomal clearance, and gut-brain axis (vagal Lewy pathology, microbiome) are increasingly recognized upstream amplifiers — particularly the gut-first Braak hypothesis, supported by hyposmia and REM-sleep behavior disorder preceding motor symptoms by 10-20 years; (3) LRRK2 G2019S and other genetic PD subtypes display Lewy- pathology variability, indicating molecular heterogeneity within the unified clinical syndrome. Anti-α-synuclein immunotherapies (prasinezumab, cinpanemab) have shown target engagement but limited clinical efficacy, suggesting aggregation may be a downstream marker rather than the rate-limiting therapeutic target.

Deep research

Falcon citations 56 citations 2026-05-23T19:21:21.440028

Show evidence (1 reference)

PMID:37048085 SUPPORT Human Clinical

"dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations"

Canonical mechanism review used as the seed reference for the hypothesis-search deep-research run.

Body-First Enteric α-Synuclein Initiation Model

body_first_enteric_alpha_synuclein_model ALTERNATIVE

Alpha-synuclein pathology initiates in the enteric nervous system or other peripheral autonomic sites, then propagates through vagal connections to the dorsal motor nucleus and broader brainstem before joining the central alpha-synuclein propagation and dopaminergic-neurodegeneration cascade. This model best explains Parkinson disease presentations with early constipation, REM-sleep behavior disorder, autonomic dysfunction, and early peripheral/cardiac sympathetic denervation.

Evidence is strongest for the gut-to-brain propagation route in animal models where truncal vagotomy or alpha-synuclein deficiency blocks spread. Human clinical and imaging studies support a body-first subtype pattern, but microbiome dysbiosis and enteric seeding remain unresolved as causal triggers versus modifiers or consequences.

Pathograph links

Gut Microbiome Dysbiosis -> Intestinal Inflammation and Barrier Dysfunction INDIRECT UNKNOWN INTERMEDIATES PD-associated dysbiosis may promote a pro-inflammatory intestinal state and barrier dysfunction, but the direction and necessity of this link remain unresolved in humans.

Intestinal Inflammation and Barrier Dysfunction -> Enteric Alpha-Synuclein Seeding INDIRECT UNKNOWN INTERMEDIATES Local gut inflammation and barrier leakiness may increase enteric alpha-synuclein expression or amyloidogenic exposure, providing a permissive setting for enteric alpha-synuclein seeding.

Enteric Alpha-Synuclein Seeding -> Vagal-Brainstem Alpha-Synuclein Propagation DIRECT Enteric alpha-synuclein seeds can propagate first to vagal brainstem nuclei and then to additional brain regions.

Enteric Alpha-Synuclein Seeding -> Constipation UNKNOWN Enteric or autonomic involvement is a plausible contributor to early constipation in body-first PD, but this edge remains clinically inferred.

Vagal-Brainstem Alpha-Synuclein Propagation -> Alpha-Synuclein Aggregation INDIRECT KNOWN INTERMEDIATES Vagal-brainstem propagation links gut-origin pathology to the broader central alpha-synuclein aggregation cascade. Intermediates: dorsal motor nucleus and nucleus tractus solitarius involvement; caudal hindbrain and higher brain region propagation

Show evidence (3 references)

PMID:38519273 SUPPORT Human Clinical

"the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."

Recent review-level synthesis of human imaging, clinical, and pathology studies explicitly frames enteric-origin body-first PD as an alternative subtype within the ASOC model.

PMID:31255487 SUPPORT Model Organism

"Truncal vagotomy and α-syn deficiency prevented the gut-to-brain spread of α-synucleinopathy and associated neurodegeneration and behavioral deficits."

Mouse gut-to-brain transmission experiments support the vagus nerve and alpha-synuclein as required components of the body-first propagation route.

PMID:39241780 SUPPORT Model Organism

"Truncal vagotomy and α-Syn deficiency significantly inhibited synucleinopathy or tauopathy spreading."

Gut-inducible mouse models provide independent support that vagotomy and alpha-synuclein deficiency inhibit gut-origin propagation into the brain.

Brain-First Central α-Synuclein Initiation Model

brain_first_central_alpha_synuclein_model ALTERNATIVE

Alpha-synuclein pathology initiates within central nervous system sites such as the olfactory bulb or amygdala and spreads centrifugally to brainstem and peripheral autonomic structures. This model best explains Parkinson disease presentations where central dopaminergic or olfactory involvement precedes prominent autonomic and enteric manifestations.

The model is supported mainly by subtype-level human imaging, clinical, and neuropathological patterns. It competes with, rather than refutes, the body-first model because both origin routes may exist within clinically diagnosed Parkinson disease.

Pathograph links

Central Alpha-Synuclein Initiation -> Alpha-Synuclein Aggregation INDIRECT KNOWN INTERMEDIATES Central initiation feeds into the broader alpha-synuclein aggregation and propagation cascade through connected brain networks. Intermediates: central network propagation from olfactory bulb or amygdala

Show evidence (3 references)

PMID:38519273 SUPPORT Human Clinical

"the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."

The ASOC model explicitly defines an olfactory bulb/amygdala origin as the brain-first subtype that competes with the enteric body-first route.

PMID:38519273 SUPPORT Human Clinical

"These subtypes should be distinguishable early in the disease course on a range of imaging, clinical, and neuropathological markers."

Human subtype distinguishability supports representing brain-first and body-first disease routes as alternative mechanistic hypothesis groups.

PMID:32830221 SUPPORT Human Clinical

"the PDRBD- data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal."

Primary multimodal imaging data support a brain-first trajectory in RBD-negative de novo PD, where central dopaminergic dysfunction appears before peripheral autonomic marker loss.

Discussions and Knowledge Gaps

In body-first Parkinson disease, are gut microbiome dysbiosis and intestinal barrier/inflammatory changes causal triggers for enteric alpha-synuclein seeding, modifiers that amplify an already initiated synucleinopathy, or secondary consequences of autonomic gut dysfunction?

KNOWLEDGE GAP OPEN gap_pd_microbiome_causal_direction_body_first

Attached to

pathophysiology#Gut Microbiome Dysbiosis pathophysiology#Intestinal Inflammation and Barrier Dysfunction pathophysiology#Enteric Alpha-Synuclein Seeding pathophysiology#Vagal-Brainstem Alpha-Synuclein Propagation

Cross-sectional human studies support PD-associated dysbiosis and elevated intestinal inflammatory/permeability markers, while animal studies support gut-to-brain alpha-synuclein propagation through the vagus nerve. The unresolved step is temporal and causal: whether dysbiosis or barrier dysfunction initiates enteric alpha-synuclein misfolding in humans, merely accelerates propagation, or appears after autonomic denervation has already altered gut physiology.

Proposed experiments

Prodromal microbiome-barrier alpha-synuclein longitudinal cohort

longitudinal prodromal multi-omics cohort study

exp_pd_prodromal_microbiome_barrier_alpha_syn_longitudinal_cohort

Follow iRBD-, constipation-, and hyposmia-enriched prodromal cohorts with serial stool metagenomics, SCFA/metabolite profiling, fecal and serum calprotectin/zonulin, autonomic imaging, and standardized enteric alpha-synuclein biopsy assays before motor conversion.

Readouts

Microbiome dysbiosis trajectory

pathophysiology#Gut Microbiome Dysbiosis

Determine whether reproducible microbiome shifts precede, track with, or follow enteric alpha-synuclein and autonomic biomarker changes.

shotgun metagenomic sequencing fecal metabolomics

Direction: POSITIVE

Intestinal inflammation and barrier trajectory

pathophysiology#Intestinal Inflammation and Barrier Dysfunction

Measure whether inflammatory and permeability markers rise before enteric alpha-synuclein detection and clinical conversion.

calprotectin assay zonulin assay

Direction: POSITIVE

Enteric alpha-synuclein seeding

pathophysiology#Enteric Alpha-Synuclein Seeding

Track phosphorylated or aggregated alpha-synuclein in standardized enteric biopsies as a candidate initiating event.

immunohistochemistry alpha-synuclein seed amplification assay

Direction: POSITIVE

Decision criterion

Microbiome and barrier changes would support a trigger model only if they reproducibly precede enteric alpha-synuclein positivity and autonomic denervation in converters; changes that follow autonomic dysfunction would support a consequence or modifier model.

Would support

pathophysiology#Gut Microbiome Dysbiosis pathophysiology#Intestinal Inflammation and Barrier Dysfunction pathophysiology#Enteric Alpha-Synuclein Seeding

Show evidence (2 references)

PMID:34220443 SUPPORT Human Clinical

"A causal relationship has not been established, but gut dysbiosis is prevalent in PD and may lead to intestinal inflammation and barrier dysfunction."

The human marker study states the core causal-direction uncertainty motivating this knowledge gap.

PMID:36332796 SUPPORT Other

"However, it remains unclear how these mechanisms relate to sporadic PD, a more common form of PD."

Review-level synthesis highlights uncertainty about how gut-related mechanisms map onto sporadic PD pathogenesis.

Which Parkinson disease risk and causal variants produce convergent dopaminergic-neuron mechanisms in a controlled human genetic background, and which phenotypes are variant-specific, modifier-dependent, or culture artifacts?

KNOWLEDGE GAP OPEN gap_pd_variant_specific_isogenic_hpsc_mechanisms

Attached to

pathophysiology#Dopaminergic Neuron Loss pathophysiology#Alpha-Synuclein Aggregation pathophysiology#Mitochondrial Dysfunction pathophysiology#Autophagy-Lysosome Pathway Dysfunction

Patient-derived iPSC comparisons are powerful but confounded by background genetic variation. Large WGS-QC'd isogenic hPSC panels, differentiated into midbrain dopaminergic neurons and phenotyped with imaging and sequencing, can separate variant-specific causal mechanisms from shared downstream neurodegenerative states.

Proposed experiments

Automated isogenic hPSC Parkinson variant panel

high-throughput isogenic stem-cell perturbation experiment

exp_pd_automated_isogenic_hpsc_variant_panel

Generate or extend a WGS-QC'd isogenic hPSC panel carrying high-risk or causal Parkinson disease alleles, differentiate lines into midbrain dopaminergic neurons, and benchmark variant-specific effects on alpha-synuclein handling, mitochondrial state, lysosomal function, and dopaminergic-neuron survival.

Model systems

Genome-edited hPSC-derived midbrain dopaminergic neuron panel

Isogenic human pluripotent stem cell collection carrying Parkinson disease variants, differentiated into disease-relevant dopaminergic neurons for mechanism-resolved phenotyping.

IPSC DERIVED MODEL PMID:38405931 link

human NCBITaxon:9606

midbrain dopaminergic neuron CL:0000700

Designed to be compatible with automated hPSC genome-engineering and clonal QC workflows such as ATTIS-style high-throughput line generation.

Perturbations

Parkinson disease variant editing

pathophysiology#Dopaminergic Neuron Loss

Introduce or compare causal and high-risk Parkinson alleles in a shared genetic background.

SNCA hgnc:11138 LRRK2 hgnc:18618 GBA1 hgnc:4177 PINK1 hgnc:14581 PRKN hgnc:8607

Prime-editing generation or correction

gene#LRRK2

Use prime editing or correction to create reciprocal disease and rescue alleles where feasible.

LRRK2 hgnc:18618

Readouts

Alpha-synuclein aggregation burden

pathophysiology#Alpha-Synuclein Aggregation

High-content imaging and biochemical readouts of alpha-synuclein accumulation in differentiated dopaminergic neurons.

high-content imaging immunocytochemistry

Direction: POSITIVE

Mitochondrial dysfunction

pathophysiology#Mitochondrial Dysfunction

Mitochondrial respiration, membrane-potential, and stress-state measurements across edited variants and corrected controls.

mitochondrial organization GO:0007005

mitochondrial respiration assay

Direction: NEGATIVE

Autophagy-lysosome pathway dysfunction

pathophysiology#Autophagy-Lysosome Pathway Dysfunction

Lysosomal function, autophagic flux, and transcriptomic readouts stratified by causal allele and rescue status.

autophagy GO:0006914

lysosomal function assay single-cell transcriptomic profiling

Direction: NEGATIVE

Dopaminergic neuron survival and identity

pathophysiology#Dopaminergic Neuron Loss

Cell survival, dopaminergic identity, and dopamine biosynthesis readouts after differentiation.

dopamine biosynthetic process GO:0042416

high-content imaging targeted transcriptomic profiling

Direction: NEGATIVE

Controls

Isogenic unedited parental hPSC line

Same genetic background without Parkinson-associated edits.

Corrected rescue alleles

Reciprocal correction of disease alleles where editing design allows.

Decision criterion

A mechanism is prioritized when multiple independently edited clones for the same variant show a reproducible phenotype that is attenuated by isogenic correction and maps to a declared pathophysiology node.

Would support

pathophysiology#Alpha-Synuclein Aggregation pathophysiology#Mitochondrial Dysfunction pathophysiology#Autophagy-Lysosome Pathway Dysfunction pathophysiology#Dopaminergic Neuron Loss

Would refute

pathophysiology#Alpha-Synuclein Aggregation pathophysiology#Mitochondrial Dysfunction pathophysiology#Autophagy-Lysosome Pathway Dysfunction

Show evidence (3 references)

PMID:38405931 SUPPORT In Vitro

"we generated a collection of 65 human stem cell lines genetically engineered to harbor high risk or causal variants in genes associated with PD"

Demonstrates the feasibility of a large isogenic hPSC Parkinson variant collection for mechanism-resolved experiments.

PMID:38405931 SUPPORT In Vitro

"rigorous quality controls, including whole-genome sequencing of each line."

Supports WGS-QC as a design requirement for the proposed panel.

+ 1 more reference

Show evidence (1 reference)

PMID:38405931 PARTIAL In Vitro

"Our iSCORE-PD collection represents an easily accessible and valuable platform to study PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting."

Establishes the existence of a human isogenic hPSC resource for studying Parkinson molecular pathophysiology, while the specific knowledge gap remains the standardized phenotype-to-mechanism adjudication.

Weight loss is a long-observed non-motor symptom of Parkinson disease, yet its mechanisms remain incompletely understood. Which of the proposed pathways — metabolic dysregulation, neuroendocrine disruption, gastrointestinal dysfunction, cognitive decline, and pharmacologic effects — are primary drivers versus secondary consequences, and how do they interact across the disease course?

KNOWLEDGE GAP OPEN gap_pd_weight_loss_multifactorial_mechanisms

Attached to

pathophysiology#Dopaminergic Neuron Loss pathophysiology#Intestinal Inflammation and Barrier Dysfunction pathophysiology#Basal Ganglia Circuit Dysfunction

Weight loss exerts substantial morbidity and mortality in PD, yet limited mechanistic understanding constrains treatment options. The Gabriel et al. (2026) review identifies six interacting pathways: (1) metabolic dysregulation (altered energy expenditure or intake), (2) neuroendocrine disruption (leptin/ghrelin/GLP-1 signaling), (3) gastrointestinal dysfunction (dysmotility, malabsorption, barrier dysfunction), (4) cognitive decline (reduced appetite awareness), (5) dopaminergic-medication effects (appetite suppression), and (6) brain stimulation paradoxes (DBS-induced weight changes). The relative contribution and temporal ordering of these mechanisms remain unknown. Resolving cross-mechanism interactions would enable targeted metabolic interventions in PD.

Proposed experiments

Longitudinal weight loss phenotype stratification with multi-mechanism readouts

longitudinal multi-omics observational cohort study

exp_pd_weight_loss_longitudinal_mechanisms

Follow a large PD cohort with serial body composition (DXA, bioimpedance), resting metabolic rate, circulating metabolic hormones (leptin, adiponectin, GLP-1, ghrelin), dopamine-agonist doses and appetite-affecting medications, cognitive testing, gastrointestinal symptom questionnaires, and GI transit imaging. Stratify the cohort into weight-loss phenotypes (progressive vs. stable) and identify mechanistic signatures.

Readouts

Metabolic rate and body composition trajectories

pathophysiology#Dopaminergic Neuron Loss

Measure resting metabolic rate, energy expenditure, and changes in lean vs. fat mass to distinguish metabolic dysregulation from reduced intake.

indirect calorimetry dual-energy X-ray absorptiometry

Direction: NEGATIVE

Circulating neuroendocrine hormone patterns

pathophysiology#Dopaminergic Neuron Loss

Quantify leptin, ghrelin, adiponectin, GLP-1, and other appetite- regulating hormones to identify dysregulation of satiety/hunger signaling.

serum hormone quantification

Direction: NEGATIVE

Gastrointestinal function and symptoms

pathophysiology#Intestinal Inflammation and Barrier Dysfunction

Assess gastric emptying (breath test), small-bowel transit, colonic function, permeability markers (zonulin, calprotectin), and GI symptom severity to establish causal vs. consequential GI involvement.

gastric-emptying scintigraphy fecal calprotectin assay

Direction: NEGATIVE

Cognitive decline severity

pathophysiology#Basal Ganglia Circuit Dysfunction

Administer validated cognitive batteries (MoCA, MMSE) and assess appetite awareness to test the cognitive-suppression hypothesis.

cognitive assessment battery

Direction: NEGATIVE

Decision criterion

Mechanistic dominance is supported by: (1) trajectories preceding or independent of weight loss (dysmetabolism, hormone changes, GI dysfunction); (2) stratification of the cohort into mechanistically distinct weight-loss phenotypes; (3) reproducible associations between mechanism-specific markers and subsequent weight-loss progression in converters.

Would support

pathophysiology#Dopaminergic Neuron Loss pathophysiology#Intestinal Inflammation and Barrier Dysfunction pathophysiology#Basal Ganglia Circuit Dysfunction

Show evidence (2 references)

PMID:41781031 SUPPORT Other

"weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood. This limited mechanistic insight has left few treatment options for weight loss in PD."

The Gabriel et al. review establishes weight loss as a significant yet mechanistically unexplained PD symptom, directly motivating this knowledge gap.

PMID:41781031 SUPPORT Other

"Emerging research highlights the role of metabolic regulation, neuroendocrine signaling, pharmacologic treatment, cognitive decline, gastrointestinal dysfunction, and brain stimulation in shaping weight trajectories in PD."

This enumerates the six candidate mechanisms for weight loss in PD, supporting the multi-pathway framing of the gap.

⚙

Pathophysiology

Dopaminergic Neuron Loss

Progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta is the core neuropathological lesion of Parkinson's disease. Motor signs emerge once an estimated 60-80% of these neurons are lost and the resulting loss of nigrostriatal dopamine input can no longer be compensated.

Dopaminergic Neuron CL:0000700

Dopamine Biosynthesis GO:0042416

substantia nigra UBERON:0002038

Downstream

Striatal Dopamine Deficiency Degeneration of substantia nigra pars compacta neurons removes the nigrostriatal projection, depleting dopamine in the striatum.

Show evidence (1 reference)

PMID:37048085 SUPPORT

"Tremor, shaking, movement problems, and difficulty with balance and coordination are among the hallmarks, and dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations."

This review confirms that dopaminergic neuronal loss in the substantia nigra pars compacta is a pathological hallmark of Parkinson's disease, supporting the core mechanism of dopaminergic neuron degeneration.

Striatal Dopamine Deficiency

Degeneration of nigrostriatal dopaminergic terminals depletes dopamine in the striatum, the principal input nucleus of the basal ganglia. Reduced striatal dopamine withdraws normal modulation of medium spiny projection neurons and is the proximate biochemical deficit linking nigral neuron loss to the motor features of Parkinson's disease.

Striatal medium spiny neuron CL:1001474

Dopaminergic synaptic transmission GO:0001963 ↓ DECREASED Dopamine Secretion GO:0014046 ↓ DECREASED

striatum UBERON:0002435

Computational models

Whole Dopaminergic Neuron SBML Model KINETIC Models dopamine synthesis, storage, release, reuptake, and degradation in dopaminergic-neuron physiology.

Downstream

Basal Ganglia Circuit Dysfunction Loss of striatal dopamine unbalances the direct and indirect basal ganglia pathways.

Show evidence (1 reference)

PMID:28332488 SUPPORT

"Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."

This review identifies striatal dopamine deficiency as a defining neuropathological hallmark of Parkinson's disease.

Basal Ganglia Circuit Dysfunction

Striatal dopamine loss shifts the basal ganglia-thalamocortical motor circuit toward excessive inhibitory output: the indirect pathway becomes hyperactive and the direct pathway hypoactive, increasing inhibitory drive from the globus pallidus pars interna onto the motor thalamus and cortex. This aberrant circuit activity, rather than neuron loss alone, generates the cardinal motor signs of Parkinson's disease.

Striatal medium spiny neuron CL:1001474 GABAergic neuron CL:0000617

GABAergic synaptic transmission GO:0051932 ↕ DYSREGULATED

basal ganglia UBERON:0002420

Computational models

Basal Ganglia Spiking Neural Network PHYSIOLOGICAL Models dopamine-modulated basal ganglia circuit dynamics, beta-band oscillations, and DBS effects.

Downstream

Resting Tremor

Bradykinesia

Rigidity

Postural Instability

Show evidence (2 references)

PMID:18781672 SUPPORT

"The parkinsonian state is characterized by disruption of the internal balance of the BG leading to hyperactivity in the two main entry points of the network (striatum and STN) and excessive inhibitory output from the GPi."

This review characterizes the parkinsonian basal ganglia by disrupted internal balance and excessive inhibitory GPi output, supporting basal ganglia circuit dysfunction as a distinct mechanism node.

PMID:30897356 SUPPORT

"We will then describe the basal ganglia-thalamocortical circuit, the major locus of PD-related circuit dysfunction, and some of the models that have influenced its study."

This review identifies the basal ganglia-thalamocortical circuit as the major locus of PD-related circuit dysfunction.

Alpha-Synuclein Aggregation

Misfolded alpha-synuclein protein accumulates to form Lewy bodies and Lewy neurites. These aggregates spread through the nervous system in a prion-like manner, contributing to neurodegeneration.

inclusion body assembly GO:0070841

Computational models

Alpha-Synuclein Aggregation BST Model KINETIC Models alpha-synuclein aggregation kinetics and degradation-pathway effects in dopaminergic neurons.

Alpha-Synuclein Prion-like Spreading Model AGENT BASED Models connectome-based propagation of misfolded alpha-synuclein pathology.

Downstream

Dopaminergic Neuron Loss

Neuroinflammation

Show evidence (3 references)

PMID:38245249 SUPPORT

"Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein."

This authoritative Lancet review establishes that aggregated α-synuclein deposition is a defining feature of Parkinson's disease pathogenesis.

PMID:38245249 SUPPORT

"Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development..."

This provides direct evidence for the prion-like spreading mechanism of α-synuclein pathology across neural networks, supporting the mechanism of trans-neuronal propagation.

PMID:36598534 SUPPORT

"Parkinson's disease (PD) is the second most common neurodegenerative disease, and is characterized by accumulation of α-synuclein (α-syn)."

Confirms that α-synuclein accumulation is a key pathological characterization of PD, reinforcing the central role of protein aggregation in disease pathology.

Mitochondrial Dysfunction

Impaired mitochondrial function, particularly complex I deficiency, leads to oxidative stress and neuronal death. Multiple PD genes (PINK1, Parkin, DJ-1) regulate mitochondrial quality control.

mitochondrion organization GO:0007005

Computational models

Whole Dopaminergic Neuron SBML Model KINETIC Models mitochondrial metabolism alongside dopamine handling in dopaminergic neurons.

Downstream

Dopaminergic Neuron Loss

Show evidence (3 references)

PMID:38245249 SUPPORT

"At a cellular level, abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease, suggesting multiple potential treatment approaches."

This establishes that mitochondrial dysfunction is a common cellular feature across both genetic and sporadic forms of PD, supporting its central role in disease pathogenesis.

PMID:25611507 SUPPORT

"Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in..."

This directly supports the role of PINK1 and Parkin genes in mitochondrial quality control and confirms that mitochondrial damage is involved in PD pathogenesis.

PMID:27911343 SUPPORT

"For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease. The identifications of mutations in genes encoding PINK1 (PTEN-induced kinase 1) and Parkin (E3 ubiquitin ligase) in familial PD and..."

This review confirms the long-standing central role of mitochondrial dysfunction in PD and validates the connection between PINK1/Parkin mutations and mitochondrial quality control defects.

Neuroinflammation

Activated microglia and astrocytes contribute to neurodegeneration through release of pro-inflammatory cytokines and oxidative stress.

Microglia CL:0000129 Astrocyte CL:0000127

Downstream

Dopaminergic Neuron Loss

Complement C3-C3aR Activation in Depression Microglial neuroinflammation drives complement cascade activation (C3-C3aR axis) as part of the broader innate immune response, with convergent upregulation of complement and coagulation pathways in depression associated with PD. This complement-mediated branch contributes to depression-like behavior via microglial synaptic pruning, distinct from dopaminergic motor pathology.

Show evidence (3 references)

PMID:38245249 SUPPORT

"Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease."

This establishes that maladaptive immune and inflammatory responses play an active role in accelerating PD pathogenesis, supporting the neuroinflammation mechanism.

PMID:37048085 SUPPORT

"Neuroinflammation has emerged as an involving mechanism at the initiation and development of PD. It is a complex network of interactions comprising immune and non-immune cells in addition to mediators of the immune response. Microglia, the resident macrophages in the CNS, take on the leading..."

This directly supports the role of microglia-mediated neuroinflammation in PD initiation and progression, confirming the importance of microglial activation in disease pathology.

PMID:36598534 SUPPORT

"Neuroinflammation driven by microglia is an important pathological manifestation of PD. α-Syn is a crucial marker of PD, and its accumulation leads to microglia M1-like phenotype polarization, activation of NLRP3 inflammasomes, and impaired autophagy and phagocytosis in microglia."

This links α-synuclein accumulation to microglial activation and pro-inflammatory M1 phenotype polarization, supporting the mechanism by which neuroinflammation contributes to neurodegeneration in PD.

Complement C3-C3aR Activation in Depression

Elevated complement cascade activation, particularly the C3-C3aR signaling axis, drives microglial synaptic engulfment and loss. In depression associated with Parkinson disease, hippocampal complement components (C1Q, C3, C3aR) and downstream signaling (p-STAT3, p-P65) are upregulated, promoting microglial phagocytosis of synapses and contributing to depressive symptoms. This represents a distinct complement-mediated pathogenic pathway in depression, separable from canonical dopaminergic motor circuit involvement.

Microglia CL:0000129

complement activation GO:0006956 ↑ INCREASED synapse pruning GO:0098883 ↑ INCREASED

hippocampal formation UBERON:0002421

Downstream

Depression Complement C3-C3aR-mediated microglial synaptic engulfment leads to hippocampal synaptic loss and dysfunction, manifesting as depression and mood disturbance in Parkinson disease.

Show evidence (3 references)

PMID:42263400 SUPPORT Model Organism

"In MPTP-treated male and female mice, hippocampal complement components (C1Q, C3, C3aR) and downstream signalling (p-STAT3, p-P65) were elevated, accompanied by microglial synapse phagocytosis and depressive-like behaviours."

MPTP mouse model demonstrates upregulation of complement cascade components in hippocampus alongside microglial synaptic phagocytosis and depression-like behaviors, establishing the complement pathway as a mechanism driving depression in PD.

PMID:42263400 SUPPORT Human Clinical

"DPD exhibits distinct sex-specific immune signatures, with convergent complement pathway activation driving microglial synaptic pruning and depressive symptoms."

Human plasma proteomic analysis from PPMI cohort reveals that depression in PD exhibits sex-specific complement pathway dysregulation, establishing complement activation as a mechanism contributing to depressive symptoms.

PMID:42263400 SUPPORT Model Organism

"The antidepressant effect of BoNT/A is mediated through inhibition of the C3-C3aR signalling axis."

Mouse model studies demonstrate that complement pathway inhibition (via BoNT/A blocking C3-C3aR signaling) alleviates depressive-like symptoms and reduces microglial synaptic engulfment, providing mechanistic validation of C3-C3aR as a therapeutic target in depression.

Autophagy-Lysosome Pathway Dysfunction

Impairment of the autophagy-lysosome pathway disrupts clearance of misfolded proteins including alpha-synuclein. Multiple PD genes (GBA, LRRK2, VPS35, ATP13A2) regulate lysosomal function, and their mutations impair protein degradation capacity leading to toxic protein accumulation.

Dopaminergic Neuron CL:0000700

Autophagy GO:0006914 Chaperone-mediated Autophagy GO:0061684

Downstream

Alpha-Synuclein Aggregation

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:31761667 SUPPORT

"In recent years, multiple lines of evidence from human genetic and molecular studies have highlighted the importance of the autophagy lysosomal pathway (ALP) in Parkinson's disease (PD). Genes such as GBA and LRRK2, which harbor some of the most common mutations associated with PD, have..."

This review establishes the genetic basis for autophagy-lysosome dysfunction in PD, identifying key genes and their mechanistic roles.

Gut Microbiome Dysbiosis

Parkinson disease cohorts show reproducible but modest gut microbiome shifts, including depletion of short-chain-fatty-acid-producing taxa and enrichment of genera linked to mucin or inflammatory biology. In the body-first model, dysbiosis is modeled as a plausible upstream trigger or modifier of intestinal inflammation and barrier dysfunction, not as an established direct cause of alpha-synuclein initiation.

Body-First Enteric α-Synuclein Initiation Model

Enteroendocrine Cell CL:0000164

intestine UBERON:0000160

Downstream

Intestinal Inflammation and Barrier Dysfunction PD-associated dysbiosis may promote a pro-inflammatory intestinal state and barrier dysfunction, but the direction and necessity of this link remain unresolved in humans.

Show evidence (2 references)

PMID:33692356 SUPPORT Human Clinical

"We found significant alterations in the PD-associated microbiome, which are robust to study-specific technical heterogeneities, although differences in microbiome structure between PD and controls are small."

Meta-analysis across ten 16S datasets supports a reproducible PD-associated gut microbiome signature, while noting small effect sizes.

PMID:36332796 SUPPORT Other

"Alterations in the gut microbiome and associated metabolites may contribute to pathogenesis in PD."

Review-level evidence supports gut microbiome changes as plausible contributors to PD pathogenesis, but not as proven initiators.

Intestinal Inflammation and Barrier Dysfunction

Sporadic Parkinson disease is associated with elevated intestinal inflammatory and permeability markers. These changes may create a local milieu that increases alpha-synuclein expression or exposes enteric neurons to amyloidogenic microbial or dietary compounds, but whether they initiate body-first PD or arise secondary to gut autonomic dysfunction remains open.

Body-First Enteric α-Synuclein Initiation Model

Inflammatory Response GO:0006954

Downstream

Enteric Alpha-Synuclein Seeding Local gut inflammation and barrier leakiness may increase enteric alpha-synuclein expression or amyloidogenic exposure, providing a permissive setting for enteric alpha-synuclein seeding.

Show evidence (2 references)

PMID:34220443 SUPPORT Human Clinical

"Calprotectin and zonulin are markers of intestinal inflammation and barrier permeability, respectively."

Establishes the measured marker interpretation for this intestinal inflammation and barrier dysfunction node.

PMID:34220443 SUPPORT Human Clinical

"Mean calprotectin was higher in PD, both in serum (14.26 mcg/ml ± 4.50 vs. 5.94 mcg/ml ± 3.80, p = 0.0125) and stool (164.54 mcg/g ± 54.19 vs. 56.19 mcg/g ± 35.88, p = 0.0048)."

Case-control data support elevated intestinal inflammatory markers in PD.

Enteric Alpha-Synuclein Seeding

In the body-first model, misfolded alpha-synuclein appears first in enteric or peripheral autonomic neural tissue and serves as the initiating seed for subsequent gut-to-brain spread. Direct causal support comes primarily from animal models that seed pathologic alpha-synuclein in the gastrointestinal wall.

Body-First Enteric α-Synuclein Initiation Model

Enteric Neuron CL:0007011

inclusion body assembly GO:0070841

enteric nervous system UBERON:0002005

Downstream

Vagal-Brainstem Alpha-Synuclein Propagation Enteric alpha-synuclein seeds can propagate first to vagal brainstem nuclei and then to additional brain regions.

Constipation Enteric or autonomic involvement is a plausible contributor to early constipation in body-first PD, but this edge remains clinically inferred.

Show evidence (2 references)

PMID:31255487 SUPPORT Model Organism

"fibrils were injected into the duodenal and pyloric muscularis layer"

The gut-to-brain transmission model experimentally seeds pathologic alpha-synuclein in the gastrointestinal wall.

PMID:34220443 PARTIAL Human Clinical

"The coexistence of an amyloidogenic gut microbiota with intestinal inflammation (leading to local overexpression of alpha-synuclein) and altered intestinal barrier permeability (exposing alpha-synuclein to the amyloidogenic xenobiotics) may play a key role in triggering the initial..."

Human review/discussion within the marker study supports enteric alpha-synuclein seeding as a plausible but not proven event in some sporadic PD cases.

Vagal-Brainstem Alpha-Synuclein Propagation

Pathologic alpha-synuclein seeded in the gastrointestinal wall can propagate through vagal connections to the dorsal motor nucleus, nucleus tractus solitarius, caudal hindbrain, and ultimately midbrain and forebrain regions. Vagotomy experiments provide the strongest causal evidence for this body-first conduit.

Body-First Enteric α-Synuclein Initiation Model

vagus nerve UBERON:0001759 midbrain UBERON:0001891

Downstream

Alpha-Synuclein Aggregation Vagal-brainstem propagation links gut-origin pathology to the broader central alpha-synuclein aggregation cascade.

Show evidence (2 references)

PMID:31255487 SUPPORT Model Organism

"Analysis of human pathology led Braak to postulate that α-synuclein (α-syn) pathology could spread from the gut to brain via the vagus nerve."

Establishes the gut-to-brain vagal propagation hypothesis tested by the mouse transmission model.

PMID:39241780 SUPPORT Model Organism

"α-Syn and Tau co-pathology can propagate from the gut to the brain, triggering behavioral disorders."

Supports gut-to-brain propagation in a gut-inducible transgenic mouse system.

Central Alpha-Synuclein Initiation

In the brain-first model, the initial alpha-synuclein pathology begins in central sites such as the olfactory bulb or amygdala, then spreads through connected brain regions and later to peripheral autonomic structures. This node captures the competing central-origin route without asserting that it applies to all Parkinson disease.

Brain-First Central α-Synuclein Initiation Model

Dopaminergic Neuron CL:0000700

inclusion body assembly GO:0070841

olfactory bulb UBERON:0002264 amygdala UBERON:0001876

Downstream

Alpha-Synuclein Aggregation Central initiation feeds into the broader alpha-synuclein aggregation and propagation cascade through connected brain networks.

Show evidence (2 references)

PMID:38519273 SUPPORT Human Clinical

"Molecular imaging studies were generally in agreement with the model, whereas structural imaging studies, such as MRI volumetry, showed conflicting findings."

Review-level synthesis supports the brain-first/body-first model while noting that not all imaging modalities agree.

PMID:32830221 SUPPORT Human Clinical

"the PDRBD- data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal."

Primary PET, MIBG, MRI, and gut-transit imaging evidence supports the central-first route by identifying a de novo PD subgroup with primary putaminal dopaminergic dysfunction followed by peripheral autonomic loss.

Oxidative Stress

Excessive reactive oxygen species from dopamine metabolism and mitochondrial dysfunction causes lipid peroxidation, protein carbonylation, and DNA damage. Dopamine auto-oxidation generates toxic quinones that preferentially damage substantia nigra neurons.

Dopaminergic Neuron CL:0000700

Response to Oxidative Stress GO:0006979 ROS Metabolic Process GO:0072593

Downstream

Mitochondrial Dysfunction

Dopaminergic Neuron Loss

Alpha-Synuclein Aggregation

Show evidence (1 reference)

PMID:37303175 SUPPORT

"Reactive oxygen species (ROS)-induced oxidative stress triggers the vicious cycle leading to the degeneration of dopaminergic neurons in the nigra pars compacta."

This review directly describes the mechanism by which oxidative stress drives dopaminergic neurodegeneration.

Calcium Dysregulation

Substantia nigra dopaminergic neurons rely on L-type calcium channels (CaV1.3) for autonomous pacemaking, making them uniquely vulnerable to calcium-mediated toxicity. Disrupted calcium homeostasis in mitochondria, ER, and lysosomes contributes to oxidative stress and cell death.

Dopaminergic Neuron CL:0000700

Calcium Ion Homeostasis GO:0055074 Calcium Ion Transport GO:0070588

Downstream

Mitochondrial Dysfunction

Oxidative Stress

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:35339179 SUPPORT

"Calcium (Ca2+) plays a central role in regulating many cellular processes and influences cell survival."

This review establishes the fundamental role of calcium channel dysregulation in PD pathogenesis.

Endoplasmic Reticulum Stress

Accumulation of misfolded proteins in the ER activates the unfolded protein response (UPR). Chronic ER stress overwhelms protective mechanisms, triggering apoptotic pathways. Alpha-synuclein aggregates and GBA mutations directly impair ER function.

Dopaminergic Neuron CL:0000700

ER Stress Response GO:0034976 Unfolded Protein Response GO:0030968

Downstream

Autophagy-Lysosome Pathway Dysfunction

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:38026955 SUPPORT

"Accumulating evidence shows that endoplasmic reticulum (ER) stress occurring in the SNpc DA neurons is an early event in the development of PD."

This review establishes ER stress as an early and central event in PD pathogenesis.

Synaptic Dysfunction

Impaired synaptic vesicle recycling, particularly defects in clathrin-mediated endocytosis, represents an early feature of PD. Multiple PD genes (DNAJC6, SYNJ1, LRRK2) regulate synaptic vesicle trafficking, and their dysfunction leads to synaptic failure before overt neurodegeneration.

Dopaminergic Neuron CL:0000700

Synaptic Vesicle Cycle GO:0099504 Synaptic Vesicle Endocytosis GO:0048488

Downstream

Dopaminergic Neuron Loss

Alpha-Synuclein Aggregation

Show evidence (1 reference)

PMID:38595283 SUPPORT

"Notably, several of these genes are linked to the synaptic vesicle recycling process, particularly the clathrin-mediated endocytosis pathway. This suggests that impaired synaptic vesicle recycling might represent an early feature of Parkinson's disease"

Establishes synaptic vesicle endocytosis dysfunction as an early feature of PD.

Iron Accumulation and Ferroptosis

Abnormal iron deposition in the substantia nigra promotes ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation. Iron catalyzes Fenton reactions generating hydroxyl radicals, and dysregulated iron metabolism contributes to oxidative damage.

Dopaminergic Neuron CL:0000700

Iron Ion Homeostasis GO:0006879 Ferroptosis GO:0097707

Downstream

Oxidative Stress

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:39218077 SUPPORT

"Parkinson's disease (PD) is a prevalent and advancing age-related neurodegenerative disorder, distinguished by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Iron regional deposit in SNpc is a significant pathological characteristic of PD."

This review establishes iron accumulation as a significant pathological characteristic and mechanistic driver of PD.

Blood-Brain Barrier Dysfunction

Altered tight junction proteins, transporter dysfunction, and alpha-synuclein accumulation compromise BBB integrity. BBB breakdown allows infiltration of peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.

Brain Endothelial Cell CL:2000044 Pericyte CL:0000669 Astrocyte CL:0000127

BBB Maintenance GO:0035633 Vascular Permeability GO:0043114

Downstream

Neuroinflammation

Dopaminergic Neuron Loss

Show evidence (1 reference)

PMID:39075566 SUPPORT

"There is increasing evidence for blood-brain barrier (BBB) alterations in Parkinson's disease (PD), the second most common neurodegenerative disorder with rapidly rising prevalence."

This comprehensive 2024 review establishes BBB dysfunction as an emerging mechanism in PD pathogenesis.

Metabolic Dysfunction and Weight Loss

Parkinson disease is associated with progressive weight loss and metabolic dysregulation through multiple interacting mechanisms. Reduced metabolic rate, dysregulated appetite-regulating hormones (leptin, ghrelin, GLP-1), gastrointestinal dysfunction, cognitive decline affecting appetite awareness, dopaminergic-medication effects, and dopamine-dependent regulation of feeding behavior all contribute to systemic metabolic failure and weight loss. Weight loss occurs in a substantial fraction of PD patients and exerts significant morbidity and mortality, yet mechanistic understanding remains incomplete.

Metabolic process GO:0008152

Downstream

Weight Loss and Nutritional Decline Metabolic dysregulation, reduced energy expenditure, neuroendocrine hormone imbalances, and gastrointestinal dysfunction converge to cause progressive weight loss and nutritional decline in PD.

Show evidence (1 reference)

PMID:41781031 SUPPORT Other

This 2026 review establishes weight loss as a significant, mechanistically complex, and undertreated symptom of Parkinson disease, establishing the rationale for a dedicated metabolic dysfunction mechanism node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

Referential integrity issues (1):

Target 'Weight Loss and Nutritional Decline' (from 'Metabolic Dysfunction and Weight Loss') not found in named elements

●

Phenotypes

Digestive 1

Constipation FREQUENT Constipation HP:0002019

Common non-motor symptom

Show evidence (1 reference)

PMID:7845407 SUPPORT

"We investigated the role of anorectal manometry in evaluating constipation and anorectal function in 15 patients with Parkinson's disease (PD) and compared results with those of 9 patients with idiopathic constipation (IC) and 8 control (C) subjects."

This study directly evaluates constipation in PD patients, supporting constipation as a common non-motor symptom.

Head and Neck 1

Hyposmia FREQUENT Hyposmia HP:0004409

Often precedes motor symptoms by years

Show evidence (1 reference)

PMID:24136244 SUPPORT

"Hyposmia, identified as reduced sensitivity to odor, is a common non-motor symptom of Parkinson's disease (PD) that antedates the typical motor symptoms by several years. It occurs in ∼90% of early-stage cases of PD."

This establishes hyposmia as a highly prevalent prodromal symptom that precedes motor symptoms, supporting its importance as an early marker of PD.

Musculoskeletal 1

Rigidity VERY_FREQUENT Rigidity HP:0002063

Cogwheel or lead-pipe rigidity

Show evidence (1 reference)

PMID:17955331 SUPPORT

"Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."

This confirms rigidity as a cardinal sign of parkinsonism relevant to PD.

Nervous System 4

Resting Tremor VERY_FREQUENT Resting tremor HP:0002322

Classic "pill-rolling" tremor at rest

Show evidence (1 reference)

PMID:17955331 SUPPORT

"Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."

This identifies resting tremor as a cardinal sign used to detect parkinsonism, supporting it as a core PD phenotype.

Bradykinesia VERY_FREQUENT Bradykinesia HP:0002067

Slowness of movement, required for diagnosis

Show evidence (1 reference)

PMID:17955331 SUPPORT

"Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."

This lists bradykinesia among the cardinal signs of parkinsonism, supporting its central role in PD.

Postural Instability FREQUENT Postural instability HP:0002172

Develops in later disease stages

Show evidence (1 reference)

PMID:17955331 SUPPORT

"Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."

This supports postural instability as a cardinal parkinsonian sign captured in PD assessments.

Depression FREQUENT Depression HP:0000716

Show evidence (1 reference)

PMID:41301797 SUPPORT

"Depressive symptoms were similar across groups, but in prodromal PD, higher GDS scores were associated with worse UPDRS III scores (p = 0.02), as well as higher freezing and fall scores."

This indicates depressive symptoms are present and clinically relevant in PD, supporting depression as a non-motor phenotype.

🧬

Genetic Associations

SNCA (Causative)

Show evidence (2 references)

PMID:9197268 SUPPORT

"A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype."

This landmark 1997 Science paper identified the first SNCA mutations in familial PD with autosomal dominant inheritance, establishing SNCA as a causative gene for Parkinson's disease.

CGGV:assertion_d21593ae-ed10-4442-8167-24f96f917302-2022-05-03T134931.425Z SUPPORT Other

ClinGen classifies the SNCA-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.

LRRK2 (Risk Factor)

Show evidence (2 references)

PMID:19945904 SUPPORT

"The LRRK2 G2019S mutation is the most frequent known cause of familial and sporadic Parkinson's disease."

This systematic review establishes that LRRK2 G2019S is the most common genetic cause of both familial and sporadic PD, supporting its role as the major genetic risk factor.

CGGV:assertion_2728e13a-b95a-4c55-8cba-082260094ecd-2021-05-03T160000.000Z SUPPORT Other

ClinGen classifies the LRRK2-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.

GBA (Risk Factor)

Show evidence (1 reference)

PMID:30097731 SUPPORT

"DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."

This identifies GBA as a genetic risk locus shared with PD, supporting its role as a PD risk factor.

PARK2 (Causative)

Show evidence (1 reference)

PMID:25611507 SUPPORT

This establishes Parkin (PARK2) as a gene mutated in autosomal recessive parkinsonism, supporting its causative role.

PINK1 (Causative)

Show evidence (2 references)

PMID:25611507 SUPPORT

This identifies PINK1 mutations in autosomal recessive parkinsonism, supporting its causative role in PD.

CGGV:assertion_1999e6c4-eb15-438a-a4ea-98989112dcbb-2023-01-18T190000.000Z SUPPORT Other

ClinGen classifies the PINK1-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.

GBA1 (Pathogenic Variants)

Gene: GBA1 hgnc:4177

Show evidence (1 reference)

CGGV:assertion_9201c03f-10de-447c-9b84-194f14b549b6-2022-05-03T134810.206Z SUPPORT Other

ClinGen classifies the GBA1-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.

PARK7 (Pathogenic Variants)

Gene: PARK7 hgnc:16369

Show evidence (1 reference)

CGGV:assertion_d79439d2-844b-4ba6-aceb-e6b179eaaa01-2022-06-27T160000.000Z SUPPORT Other

ClinGen classifies the PARK7-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.

PRKN (Pathogenic Variants)

Gene: PRKN hgnc:8607

Show evidence (1 reference)

CGGV:assertion_6b39c4a0-f6bd-4afc-b2a7-f234eab5a667-2023-01-18T190000.000Z SUPPORT Other

ClinGen classifies the PRKN-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.

VPS35 (Pathogenic Variants)

Gene: VPS35 hgnc:13487

Show evidence (1 reference)

CGGV:assertion_b0e546d6-8a44-4e9d-83aa-f781ec4ec166-2021-11-03T134517.796Z SUPPORT Other

ClinGen classifies the VPS35-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.

💊

Medical Actions

Levodopa/Carbidopa

Action: Pharmacotherapy NCIT:C15986

Agent: levodopa CHEBI:15765 carbidopa CHEBI:3395

Gold standard treatment, replaces dopamine precursor.

Mechanism Target:

RESTORES Striatal Dopamine Deficiency — Levodopa supplies dopamine precursor to partially restore dopaminergic signaling in dopamine-depleted striatal circuits.

Show evidence (1 reference)

PMID:27577098 SUPPORT

"The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."

This review identifies L-Dopa as a core pharmacotherapy for PD motor symptoms.

Dopamine Agonists

Action: Pharmacotherapy NCIT:C15986

Directly stimulate dopamine receptors.

Mechanism Target:

BYPASSES Striatal Dopamine Deficiency — Dopamine agonists bypass reduced endogenous dopamine by directly stimulating dopamine receptors in downstream circuits.

Show evidence (1 reference)

PMID:27577098 SUPPORT

This review identifies dopamine agonists as part of standard pharmacotherapy for PD.

MAO-B Inhibitors

Action: Pharmacotherapy NCIT:C15986

Prevent dopamine breakdown (selegiline, rasagiline).

Mechanism Target:

MODULATES Striatal Dopamine Deficiency — MAO-B inhibitors prolong dopamine signaling by reducing dopamine breakdown.

Show evidence (1 reference)

PMID:27577098 SUPPORT

This review lists MAO-B inhibitors among standard PD pharmacotherapies.

COMT Inhibitors

Action: Pharmacotherapy NCIT:C15986

Extend levodopa duration (entacapone).

Mechanism Target:

MODULATES Striatal Dopamine Deficiency — COMT inhibitors extend levodopa-derived dopaminergic signaling and indirectly modulate striatal dopamine deficiency.

Show evidence (1 reference)

PMID:27577098 SUPPORT

This review lists COMT inhibitors among standard PD pharmacotherapies.

Deep Brain Stimulation

Action: deep brain stimulation MAXO:0000943

Surgical therapy for advanced motor fluctuations.

Mechanism Target:

MODULATES Basal Ganglia Circuit Dysfunction — DBS modulates abnormal basal ganglia motor circuit activity rather than acting upstream on dopaminergic neuron loss.

Show evidence (1 reference)

PMID:27577098 SUPPORT

This review identifies deep brain stimulation as a standard symptomatic therapy for PD.

Physical Therapy

Action: physical therapy MAXO:0000011

Maintains mobility and reduces fall risk.

Mechanism Target:

BYPASSES Basal Ganglia Circuit Dysfunction — Physical therapy uses exercise, cueing, and compensation to work around basal ganglia motor circuit dysfunction.

Show evidence (1 reference)

PMID:27577098 SUPPORT

This review lists physiotherapy as part of symptomatic treatment for PD.

Botulinum Neurotoxin A (BoNT/A) for Depression

Action: botulinum toxin type A therapy MAXO:0009016

Botulinum toxin type A alleviates depression in Parkinson's disease by inhibiting the complement C3-C3aR signaling axis and reducing microglial synaptic phagocytosis. This represents a novel complement-targeted approach to managing depression as a non-motor symptom in PD, distinct from BoNT/A's canonical motor symptom applications.

Mechanism Target:

INHIBITS Complement C3-C3aR Activation in Depression — BoNT/A suppresses complement C3-C3aR signaling through modulation of microglial phagocytosis-related functions, reducing microglial activation and synaptic phagocytosis, thereby alleviating depression-like symptoms in PD models.

Show evidence (1 reference)

PMID:42263400 SUPPORT Model Organism

"BoNT/A treatment alleviated depressive-like behaviours and reduced microglial synaptic engulfment in an MPTP model; these therapeutic effects were abolished in C3-/- and C3aR-/- mice."

Mouse PD model demonstrates that BoNT/A alleviates depression-like behavior through inhibition of the C3-C3aR complement axis, preventing microglial synaptic engulfment and protecting against synapse loss in the hippocampus.

🌍

Environmental Factors

Pesticide Exposure

Rotenone and paraquat linked to increased risk

Show evidence (1 reference)

PMID:15177059 SUPPORT

"there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."

This review supports pesticide exposure as an environmental factor influencing PD risk.

Rural Living

Associated with pesticide/herbicide exposure

Show evidence (1 reference)

PMID:15177059 PARTIAL

"While clear links to rural living, dietary factors, exposure to metals, head injury, and exposure to infectious diseases during childhood have not been established, there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."

This review notes that clear links to rural living are not established, indicating mixed evidence for this risk factor.

Head Trauma

Possible risk factor

Show evidence (1 reference)

PMID:36781627 SUPPORT

"The risk ratio of TBI among PD and controls by a combination of 15 studies using a random-effect model was 1.48 (95% CI 1.22-1.74)."

This meta-analysis supports head trauma (TBI) as a risk factor for developing PD.

📊

Related Datasets

Large-scale metagenomics of Parkinson's disease gut microbiome sra:PRJNA834801

Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC) with over 30% of species, genes and pathways showing altered abundances in PD. Identified polymicrobial clusters and competitive relationships.

human gut metagenome WGS

fecal sample

Conditions: Parkinson's disease healthy controls

PMID:36357667

Nature Communications 2022 - largest PD metagenomics to date

Show evidence (1 reference)

PMID:37449597 SUPPORT

"This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."

This supports the relevance of gut microbiome datasets to PD mechanisms.

Multi-omics analysis of PD gut microbiome gene expression sra:PRJNA782492

Integrated metagenomics and metatranscriptomics analyzing microbiome gene co-expression networks in Parkinson's disease. Observed significant depletion of hub genes in PD patients.

human gut metagenome WGS

fecal sample

Conditions: Parkinson's disease healthy controls

npj Biofilms and Microbiomes 2025 - multi-omics approach

Show evidence (1 reference)

PMID:37449597 SUPPORT

"This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."

This supports the relevance of gut microbiome datasets to PD mechanisms.

Longitudinal gut microbiome in Parkinson's disease sra:PRJNA808166

Longitudinal study investigating gut microbiome changes in PD patients and impact of device-assisted therapies. Tracks microbiome alterations with disease progression.

human gut metagenome

fecal sample

Conditions: Parkinson's disease baseline Parkinson's disease follow-up

Frontiers Aging Neuroscience 2022 - longitudinal design

Show evidence (1 reference)

PMID:37449597 SUPPORT

"This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."

This supports the relevance of gut microbiome datasets to PD mechanisms.

PD gut microbiome meta-analysis cohort sra:PRJNA530401

Metagenomic sequencing data from PD patients and controls contributing to cross-cohort meta-analyses. Identified alterations linked to intestinal inflammation including reduced butyrate producers.

human gut metagenome WGS

fecal sample

Conditions: Parkinson's disease healthy controls

npj Parkinson's Disease 2021 - meta-analysis contributing cohort

Show evidence (1 reference)

PMID:37449597 SUPPORT

"This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."

This supports the relevance of gut microbiome datasets to PD mechanisms.

Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease metabolights:MTBLS2266

LC-MS sebum metabolomics in Parkinson's disease, including drug-naive and medicated cohorts, compared with well-matched controls to identify lipid pathway alterations.

human METABOLOMICS n=274

Conditions: Parkinson's disease drug-naive Parkinson's disease medicated Parkinson's disease healthy controls

Findings

Sebum metabolomics in PD shows alterations in lipid metabolism pathways, including the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis.

Show evidence (1 reference)

metabolights:MTBLS2266 SUPPORT

"Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis."

The dataset description reports lipid pathway alterations detected in sebum metabolomics for PD.

LC-MS profiling of 274 participants detected metabolites predictive of PD phenotype.

Show evidence (1 reference)

metabolights:MTBLS2266 SUPPORT

"We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype."

The dataset description specifies LC-MS profiling and the PD/control cohort sizes.

PMID:33707447

Metabolomics profiling of sebum as a non-invasive biofluid for PD.

Show evidence (1 reference)

metabolights:MTBLS2266 SUPPORT

"Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid."

Establishes that the dataset focuses on PD sebum metabolomics.

Metabolomic Changes in Idiopathic and GBA1 Parkinson’s Disease metabolights:MTBLS10743

Mass spectrometry metabolomics comparing idiopathic Parkinson's disease and GBA1-associated Parkinson's disease cohorts with controls.

human METABOLOMICS

Conditions: idiopathic Parkinson's disease GBA1-associated Parkinson's disease healthy controls

Findings

Metabolomic signatures differ between GBA1-PD and idiopathic PD in sebum and serum with good specificity and sensitivity.

Show evidence (1 reference)

metabolights:MTBLS10743 SUPPORT

"Differences in metabolomic signatures were seen between ... GBA1-PD and iPD in sebum and serum with good specificity and sensitivity."

The dataset description reports discriminative metabolomic signatures between GBA1-PD and idiopathic PD.

Serum pathways implicated include sphingolipid metabolism, amino sugar metabolism and amino acid pathways, while sebum features are hypothesised to be lipid degradation products.

Show evidence (1 reference)

metabolights:MTBLS10743 SUPPORT

"Significant pathways in serum included sphingolipid metabolism, amino sugar metabolism and amino acid pathways, whereas significant features between groups in sebum are hypothesised to be lipid degradation products."

The dataset description lists pathway-level differences in serum and hypothesized lipid degradation products in sebum.

Preprint dataset describing metabolic changes in idiopathic vs GBA1 PD.

Show evidence (1 reference)

metabolights:MTBLS10743 SUPPORT

"Here, we use mass spectrometry based metabolomics to analyse serum and sebum samples from 50 genotyped participants and find differences in lipid and sugar regulation, oxidative stress and the production of amino acids and neurotransmitters which distinguish ... GBA1-PD from iPD."

Establishes the dataset's serum and sebum metabolomics design distinguishing GBA1-PD from idiopathic PD.

A multi-region single nucleus transcriptomic atlas of Parkinson's disease cellxgene:d5d0df8f-4eee-49d8-a221-a288f50a1590

Single-nucleus RNA-seq atlas of Parkinson's disease spanning multiple brain regions, providing cell-type-resolved transcriptomic profiles of dopaminergic neurons and glial populations in PD and healthy controls.

human SINGLE CELL RNA SEQ

brain tissue

Conditions: Parkinson's disease healthy controls

PMID:39317733

CZI CELLxGENE collection. DOI 10.1038/s41597-024-04117-y. Multi-region snRNA-seq atlas enabling virtual cell model training on PD-relevant cell states.

🧮

Computational Models

Alpha-Synuclein Aggregation BST Model KINETIC

Biochemical Systems Theory (BST) model of alpha-synuclein aggregation kinetics in dopaminergic neurons. Integrates dopamine metabolism, ubiquitin-proteasome system, and lysosomal degradation pathways. Simulates effects of oxidative stress and proteasome inhibition on synuclein accumulation.

Repository ↗ PMID:19136028

Pathograph links

Alpha-Synuclein Aggregation Models alpha-synuclein aggregation kinetics and degradation-pathway effects in dopaminergic neurons.

First comprehensive kinetic model of PD-related protein aggregation

Whole Dopaminergic Neuron SBML Model SBML KINETIC

Large-scale Systems Biology Markup Language (SBML) model of dopaminergic neuron containing 139 reactions and 111 metabolites. Captures dopamine synthesis, vesicular storage, release, reuptake, and degradation alongside mitochondrial function and oxidative stress.

Repository ↗ PMID:24196439

Pathograph links

Striatal Dopamine Deficiency Models dopamine synthesis, storage, release, reuptake, and degradation in dopaminergic-neuron physiology.

Mitochondrial Dysfunction Models mitochondrial metabolism alongside dopamine handling in dopaminergic neurons.

Enables simulation of drug effects on dopaminergic neurotransmission

Basal Ganglia Spiking Neural Network PHYSIOLOGICAL

Computational model of the basal ganglia circuit capturing dopamine-modulated dynamics between striatum, globus pallidus, subthalamic nucleus, and substantia nigra. Simulates pathological beta-band oscillations and motor dysfunction in PD.

PMID:29666208

Pathograph links

Basal Ganglia Circuit Dysfunction Models dopamine-modulated basal ganglia circuit dynamics, beta-band oscillations, and DBS effects.

Models circuit-level effects of dopamine depletion and DBS therapy

Alpha-Synuclein Prion-like Spreading Model AGENT_BASED

Network diffusion model simulating prion-like propagation of misfolded alpha-synuclein through brain connectome. Uses graph-theoretical approach to predict spatial patterns of neurodegeneration from initial seeding sites.

Pathograph links

Alpha-Synuclein Aggregation Models connectome-based propagation of misfolded alpha-synuclein pathology.

Predicts Braak staging patterns from connectivity-based spreading

{ }

Source YAML

click to show

name: Parkinson's Disease
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-05-21T21:50:55Z'
category: Complex
parents:
- Neurodegenerative Disease
- Movement Disorder
disease_term:
  preferred_term: Parkinson disease
  term:
    id: MONDO:0005180
    label: Parkinson disease
mechanistic_hypotheses:
- hypothesis_group_id: canonical_synucleinopathy_dopaminergic_neurodegeneration_model
  hypothesis_label: Canonical α-Synucleinopathy and Dopaminergic Neurodegeneration Model
  status: CANONICAL
  description: >-
    Misfolded α-synuclein aggregates into oligomers and Lewy bodies, propagates trans-synaptically in a prion-like manner, and induces progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. The resulting striatal dopamine deficiency causes the cardinal motor signs (bradykinesia, rigidity, tremor, postural instability), while broader Lewy pathology in autonomic, brainstem, and cortical regions accounts for the non-motor symptoms (REM-sleep behavior disorder, hyposmia, constipation, cognitive impairment). Pathway evidence implicates impaired autophagy/lysosomal clearance (GBA), mitochondrial dysfunction (PINK1/Parkin), and oxidative stress as upstream amplifiers; loss of dopaminergic feedback to the indirect/direct basal ganglia circuits explains the motor circuit signature.
  notes: >-
    Retained as CANONICAL. The 2026 falcon
    hypothesis-search report
    (kb/hypotheses/Parkinsons_Disease/canonical_synucleinopathy_dopaminergic_neurodegeneration_model;
    openscientist timed out) confirms misfolded α-synuclein
    aggregation, Lewy-body formation, and progressive substantia-nigra
    pars-compacta dopaminergic neuron loss as the central
    mechanism. Three qualifications: (1) the prion-like cell-to-cell
    propagation model is well-validated in mouse and primate
    models (intracerebral PFF injection seeds endogenous
    aggregates and produces motor deficits), but its rate-limiting
    role in human sporadic PD remains debated; (2) GBA1
    heterozygosity, mitochondrial dysfunction (PINK1/Parkin),
    impaired autophagy/lysosomal clearance, and gut-brain axis
    (vagal Lewy pathology, microbiome) are increasingly
    recognized upstream amplifiers — particularly the gut-first
    Braak hypothesis, supported by hyposmia and REM-sleep
    behavior disorder preceding motor symptoms by 10-20 years;
    (3) LRRK2 G2019S and other genetic PD subtypes display Lewy-
    pathology variability, indicating molecular heterogeneity
    within the unified clinical syndrome. Anti-α-synuclein
    immunotherapies (prasinezumab, cinpanemab) have shown
    target engagement but limited clinical efficacy, suggesting
    aggregation may be a downstream marker rather than the
    rate-limiting therapeutic target.
  evidence:
  - reference: PMID:37048085
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations"
    explanation: >
      Canonical mechanism review used as the seed reference for the
      hypothesis-search deep-research run.
- hypothesis_group_id: body_first_enteric_alpha_synuclein_model
  hypothesis_label: Body-First Enteric α-Synuclein Initiation Model
  status: ALTERNATIVE
  description: >-
    Alpha-synuclein pathology initiates in the enteric nervous system or other
    peripheral autonomic sites, then propagates through vagal connections to
    the dorsal motor nucleus and broader brainstem before joining the central
    alpha-synuclein propagation and dopaminergic-neurodegeneration cascade.
    This model best explains Parkinson disease presentations with early
    constipation, REM-sleep behavior disorder, autonomic dysfunction, and
    early peripheral/cardiac sympathetic denervation.
  notes: >-
    Evidence is strongest for the gut-to-brain propagation route in animal
    models where truncal vagotomy or alpha-synuclein deficiency blocks spread.
    Human clinical and imaging studies support a body-first subtype pattern,
    but microbiome dysbiosis and enteric seeding remain unresolved as causal
    triggers versus modifiers or consequences.
  evidence:
  - reference: PMID:38519273
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."
    explanation: >-
      Recent review-level synthesis of human imaging, clinical, and pathology
      studies explicitly frames enteric-origin body-first PD as an alternative
      subtype within the ASOC model.
  - reference: PMID:31255487
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Truncal vagotomy and α-syn deficiency prevented the gut-to-brain spread of α-synucleinopathy and associated neurodegeneration and behavioral deficits."
    explanation: >-
      Mouse gut-to-brain transmission experiments support the vagus nerve and
      alpha-synuclein as required components of the body-first propagation
      route.
  - reference: PMID:39241780
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Truncal vagotomy and α-Syn deficiency significantly inhibited synucleinopathy or tauopathy spreading."
    explanation: >-
      Gut-inducible mouse models provide independent support that vagotomy and
      alpha-synuclein deficiency inhibit gut-origin propagation into the brain.
- hypothesis_group_id: brain_first_central_alpha_synuclein_model
  hypothesis_label: Brain-First Central α-Synuclein Initiation Model
  status: ALTERNATIVE
  description: >-
    Alpha-synuclein pathology initiates within central nervous system sites
    such as the olfactory bulb or amygdala and spreads centrifugally to
    brainstem and peripheral autonomic structures. This model best explains
    Parkinson disease presentations where central dopaminergic or olfactory
    involvement precedes prominent autonomic and enteric manifestations.
  notes: >-
    The model is supported mainly by subtype-level human imaging, clinical,
    and neuropathological patterns. It competes with, rather than refutes, the
    body-first model because both origin routes may exist within clinically
    diagnosed Parkinson disease.
  evidence:
  - reference: PMID:38519273
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."
    explanation: >-
      The ASOC model explicitly defines an olfactory bulb/amygdala origin as
      the brain-first subtype that competes with the enteric body-first route.
  - reference: PMID:38519273
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These subtypes should be distinguishable early in the disease course on a range of imaging, clinical, and neuropathological markers."
    explanation: >-
      Human subtype distinguishability supports representing brain-first and
      body-first disease routes as alternative mechanistic hypothesis groups.
  - reference: PMID:32830221
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the PDRBD- data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal."
    explanation: >-
      Primary multimodal imaging data support a brain-first trajectory in
      RBD-negative de novo PD, where central dopaminergic dysfunction appears
      before peripheral autonomic marker loss.
pathophysiology:
- name: Dopaminergic Neuron Loss
  conforms_to: "parkinsonism_dopaminergic_degeneration#Nigrostriatal Dopaminergic Neurodegeneration"
  description: >
    Progressive degeneration of dopaminergic neurons in the substantia nigra
    pars compacta is the core neuropathological lesion of Parkinson's disease.
    Motor signs emerge once an estimated 60-80% of these neurons are lost and
    the resulting loss of nigrostriatal dopamine input can no longer be
    compensated.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  locations:
  - preferred_term: substantia nigra
    term:
      id: UBERON:0002038
      label: substantia nigra
  biological_processes:
  - preferred_term: Dopamine Biosynthesis
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
  downstream:
  - target: Striatal Dopamine Deficiency
    causal_link_type: DIRECT
    description: >
      Degeneration of substantia nigra pars compacta neurons removes the
      nigrostriatal projection, depleting dopamine in the striatum.
    evidence:
    - reference: PMID:28332488
      reference_title: "Parkinson disease."
      supports: SUPPORT
      snippet: "Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."
      explanation: >
        This Nature Reviews Disease Primers review states that substantia nigra
        neuronal loss causes striatal dopamine deficiency, supporting this
        causal edge.
  evidence:
  - reference: PMID:37048085
    reference_title: "Microglia Mediated Neuroinflammation in Parkinson's Disease."
    supports: SUPPORT
    snippet: "Tremor, shaking, movement problems, and difficulty with balance and coordination are among the hallmarks, and dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations."
    explanation: This review confirms that dopaminergic neuronal loss in the substantia nigra pars compacta is a pathological hallmark of Parkinson's disease, supporting the core mechanism of dopaminergic neuron degeneration.
- name: Striatal Dopamine Deficiency
  conforms_to: "parkinsonism_dopaminergic_degeneration#Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction"
  description: >
    Degeneration of nigrostriatal dopaminergic terminals depletes dopamine in
    the striatum, the principal input nucleus of the basal ganglia. Reduced
    striatal dopamine withdraws normal modulation of medium spiny projection
    neurons and is the proximate biochemical deficit linking nigral neuron
    loss to the motor features of Parkinson's disease.
  cell_types:
  - preferred_term: Striatal medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: Dopaminergic synaptic transmission
    term:
      id: GO:0001963
      label: synaptic transmission, dopaminergic
    modifier: DECREASED
  - preferred_term: Dopamine Secretion
    term:
      id: GO:0014046
      label: dopamine secretion
    modifier: DECREASED
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  downstream:
  - target: Basal Ganglia Circuit Dysfunction
    causal_link_type: DIRECT
    description: >
      Loss of striatal dopamine unbalances the direct and indirect basal
      ganglia pathways.
    evidence:
    - reference: PMID:18781672
      reference_title: "Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease."
      supports: SUPPORT
      snippet: "Dopaminergic depletion in Parkinson's disease disrupts the corticostriatal balance leading to increased activity the indirect circuit and reduced activity in the direct circuit."
      explanation: >
        This review states that dopaminergic depletion disrupts the
        corticostriatal balance, raising indirect-pathway and lowering
        direct-pathway activity, supporting striatal dopamine deficiency as the
        cause of basal ganglia circuit dysfunction.
  evidence:
  - reference: PMID:28332488
    reference_title: "Parkinson disease."
    supports: SUPPORT
    snippet: "Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."
    explanation: >
      This review identifies striatal dopamine deficiency as a defining
      neuropathological hallmark of Parkinson's disease.
- name: Basal Ganglia Circuit Dysfunction
  description: >
    Striatal dopamine loss shifts the basal ganglia-thalamocortical motor
    circuit toward excessive inhibitory output: the indirect pathway becomes
    hyperactive and the direct pathway hypoactive, increasing inhibitory drive
    from the globus pallidus pars interna onto the motor thalamus and cortex.
    This aberrant circuit activity, rather than neuron loss alone, generates
    the cardinal motor signs of Parkinson's disease.
  cell_types:
  - preferred_term: Striatal medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: GABAergic synaptic transmission
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: DYSREGULATED
  locations:
  - preferred_term: basal ganglia
    term:
      id: UBERON:0002420
      label: basal ganglion
  downstream:
  - target: Resting Tremor
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:17955331
      reference_title: "The Rotterdam Study: objectives and design update."
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: >
        This identifies resting tremor as a cardinal parkinsonian sign; its
        precise circuit origin within basal ganglia dysfunction remains
        debated, so the edge directness is left UNKNOWN.
  - target: Bradykinesia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17955331
      reference_title: "The Rotterdam Study: objectives and design update."
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: This establishes bradykinesia as a cardinal parkinsonian sign downstream of basal ganglia circuit dysfunction.
    - reference: PMID:19127584
      reference_title: "The basal ganglia in Parkinson's disease: current concepts and unexplained observations."
      supports: SUPPORT
      snippet: "In the parkinsonian state, dopamine depletion shifts the BG toward inhibiting cortically generated movements by increasing the gain in the globus pallidus pars externa-subthalamic nucleus-globus pallidus pars interna network and reducing activity in \"direct\" cortico-putaminal-globus pallidus pars interna projections."
      explanation: >
        This review describes how parkinsonian basal ganglia circuit
        dysfunction inhibits cortically generated movements, supporting
        bradykinesia as a direct downstream consequence.
  - target: Rigidity
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17955331
      reference_title: "The Rotterdam Study: objectives and design update."
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: This identifies rigidity as a cardinal parkinsonian sign downstream of basal ganglia circuit dysfunction.
    - reference: PMID:19127584
      reference_title: "The basal ganglia in Parkinson's disease: current concepts and unexplained observations."
      supports: SUPPORT
      snippet: "In the parkinsonian state, dopamine depletion shifts the BG toward inhibiting cortically generated movements by increasing the gain in the globus pallidus pars externa-subthalamic nucleus-globus pallidus pars interna network and reducing activity in \"direct\" cortico-putaminal-globus pallidus pars interna projections."
      explanation: >
        This review describes dopamine-depletion-driven basal ganglia output
        changes that inhibit cortically generated movements, supporting a
        mechanistic basal ganglia circuit contribution to parkinsonian motor
        signs including rigidity.
  - target: Postural Instability
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:17955331
      reference_title: "The Rotterdam Study: objectives and design update."
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: >
        This supports impaired postural reflexes as a cardinal parkinsonian
        sign; postural instability has a recognized non-dopaminergic
        component, so the edge directness is left UNKNOWN.
  evidence:
  - reference: PMID:18781672
    reference_title: "Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease."
    supports: SUPPORT
    snippet: "The parkinsonian state is characterized by disruption of the internal balance of the BG leading to hyperactivity in the two main entry points of the network (striatum and STN) and excessive inhibitory output from the GPi."
    explanation: >
      This review characterizes the parkinsonian basal ganglia by disrupted
      internal balance and excessive inhibitory GPi output, supporting basal
      ganglia circuit dysfunction as a distinct mechanism node.
  - reference: PMID:30897356
    reference_title: "Circuit Mechanisms of Parkinson's Disease."
    supports: SUPPORT
    snippet: "We will then describe the basal ganglia-thalamocortical circuit, the major locus of PD-related circuit dysfunction, and some of the models that have influenced its study."
    explanation: >
      This review identifies the basal ganglia-thalamocortical circuit as the
      major locus of PD-related circuit dysfunction.
- name: Alpha-Synuclein Aggregation
  conforms_to: "parkinsonism_dopaminergic_degeneration#Alpha-Synuclein Aggregation and Lewy Pathology"
  description: >
    Misfolded alpha-synuclein protein accumulates to form Lewy bodies and
    Lewy neurites. These aggregates spread through the nervous system in a
    prion-like manner, contributing to neurodegeneration.
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:38245249
      reference_title: "The pathogenesis of Parkinson's disease."
      supports: SUPPORT
      snippet: "Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease."
      explanation: This indicates that α-synuclein aggregation drives disease development and progression, supporting downstream dopaminergic neuron loss.
  - target: Neuroinflammation
    evidence:
    - reference: PMID:36598534
      reference_title: "Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease."
      supports: SUPPORT
      snippet: "α-Syn is a crucial marker of PD, and its accumulation leads to microglia M1-like phenotype polarization, activation of NLRP3 inflammasomes, and impaired autophagy and phagocytosis in microglia."
      explanation: This links α-synuclein accumulation to microglial activation, supporting neuroinflammation as a downstream effect.
  evidence:
  - reference: PMID:38245249
    reference_title: "The pathogenesis of Parkinson's disease."
    supports: SUPPORT
    snippet: "Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein."
    explanation: This authoritative Lancet review establishes that aggregated α-synuclein deposition is a defining feature of Parkinson's disease pathogenesis.
  - reference: PMID:38245249
    reference_title: "The pathogenesis of Parkinson's disease."
    supports: SUPPORT
    snippet: "Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease."
    explanation: This provides direct evidence for the prion-like spreading mechanism of α-synuclein pathology across neural networks, supporting the mechanism of trans-neuronal propagation.
  - reference: PMID:36598534
    reference_title: "Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease."
    supports: SUPPORT
    snippet: "Parkinson's disease (PD) is the second most common neurodegenerative disease, and is characterized by accumulation of α-synuclein (α-syn)."
    explanation: Confirms that α-synuclein accumulation is a key pathological characterization of PD, reinforcing the central role of protein aggregation in disease pathology.
- name: Mitochondrial Dysfunction
  conforms_to: "parkinsonism_dopaminergic_degeneration#Mitochondrial Complex I Inhibition and Oxidative Stress"
  description: >
    Impaired mitochondrial function, particularly complex I deficiency,
    leads to oxidative stress and neuronal death. Multiple PD genes
    (PINK1, Parkin, DJ-1) regulate mitochondrial quality control.
  biological_processes:
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:27911343
      reference_title: "PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology?"
      supports: SUPPORT
      snippet: "For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease."
      explanation: This supports mitochondrial dysfunction as a central driver of neurodegeneration in PD, consistent with dopaminergic neuron loss.
  evidence:
  - reference: PMID:38245249
    reference_title: "The pathogenesis of Parkinson's disease."
    supports: SUPPORT
    snippet: "At a cellular level, abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease, suggesting multiple potential treatment approaches."
    explanation: This establishes that mitochondrial dysfunction is a common cellular feature across both genetic and sporadic forms of PD, supporting its central role in disease pathogenesis.
  - reference: PMID:25611507
    reference_title: "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease."
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This directly supports the role of PINK1 and Parkin genes in mitochondrial quality control and confirms that mitochondrial damage is involved in PD pathogenesis.
  - reference: PMID:27911343
    reference_title: "PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology?"
    supports: SUPPORT
    snippet: "For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease. The identifications of mutations in genes encoding PINK1 (PTEN-induced kinase 1) and Parkin (E3 ubiquitin ligase) in familial PD and their functional association with mitochondrial quality control provided further support to this hypothesis."
    explanation: This review confirms the long-standing central role of mitochondrial dysfunction in PD and validates the connection between PINK1/Parkin mutations and mitochondrial quality control defects.
- name: Neuroinflammation
  description: >
    Activated microglia and astrocytes contribute to neurodegeneration
    through release of pro-inflammatory cytokines and oxidative stress.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:37048085
      reference_title: "Microglia Mediated Neuroinflammation in Parkinson's Disease."
      supports: SUPPORT
      snippet: "Neuroinflammation has emerged as an involving mechanism at the initiation and development of PD."
      explanation: This indicates neuroinflammation contributes to PD progression, supporting dopaminergic neuron loss downstream.
  - target: Complement C3-C3aR Activation in Depression
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      Microglial neuroinflammation drives complement cascade activation (C3-C3aR axis) as part of
      the broader innate immune response, with convergent upregulation of complement and coagulation
      pathways in depression associated with PD. This complement-mediated branch contributes to
      depression-like behavior via microglial synaptic pruning, distinct from dopaminergic motor pathology.
    evidence:
    - reference: PMID:42263400
      reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In MPTP-treated male and female mice, hippocampal complement components (C1Q, C3, C3aR) and downstream signalling (p-STAT3, p-P65) were elevated, accompanied by microglial synapse phagocytosis and depressive-like behaviours."
      explanation: Mouse model demonstrates that neuroinflammatory upregulation of complement cascades drives hippocampal complement component elevation and microglial synaptic engulfment, manifesting as depressive-like behavior independent of motor phenotype.
  evidence:
  - reference: PMID:38245249
    reference_title: "The pathogenesis of Parkinson's disease."
    supports: SUPPORT
    snippet: "Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease."
    explanation: This establishes that maladaptive immune and inflammatory responses play an active role in accelerating PD pathogenesis, supporting the neuroinflammation mechanism.
  - reference: PMID:37048085
    reference_title: "Microglia Mediated Neuroinflammation in Parkinson's Disease."
    supports: SUPPORT
    snippet: "Neuroinflammation has emerged as an involving mechanism at the initiation and development of PD. It is a complex network of interactions comprising immune and non-immune cells in addition to mediators of the immune response. Microglia, the resident macrophages in the CNS, take on the leading role in regulating neuroinflammation and maintaining homeostasis."
    explanation: This directly supports the role of microglia-mediated neuroinflammation in PD initiation and progression, confirming the importance of microglial activation in disease pathology.
  - reference: PMID:36598534
    reference_title: "Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease."
    supports: SUPPORT
    snippet: "Neuroinflammation driven by microglia is an important pathological manifestation of PD. α-Syn is a crucial marker of PD, and its accumulation leads to microglia M1-like phenotype polarization, activation of NLRP3 inflammasomes, and impaired autophagy and phagocytosis in microglia."
    explanation: This links α-synuclein accumulation to microglial activation and pro-inflammatory M1 phenotype polarization, supporting the mechanism by which neuroinflammation contributes to neurodegeneration in PD.
- name: Complement C3-C3aR Activation in Depression
  description: >
    Elevated complement cascade activation, particularly the C3-C3aR signaling axis,
    drives microglial synaptic engulfment and loss. In depression associated with
    Parkinson disease, hippocampal complement components (C1Q, C3, C3aR) and downstream
    signaling (p-STAT3, p-P65) are upregulated, promoting microglial phagocytosis of
    synapses and contributing to depressive symptoms. This represents a distinct
    complement-mediated pathogenic pathway in depression, separable from canonical
    dopaminergic motor circuit involvement.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  locations:
  - preferred_term: hippocampal formation
    term:
      id: UBERON:0002421
      label: hippocampal formation
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
    modifier: INCREASED
  - preferred_term: synapse pruning
    term:
      id: GO:0098883
      label: synapse pruning
    modifier: INCREASED
  downstream:
  - target: Depression
    causal_link_type: DIRECT
    description: >
      Complement C3-C3aR-mediated microglial synaptic engulfment leads to hippocampal
      synaptic loss and dysfunction, manifesting as depression and mood disturbance
      in Parkinson disease.
    evidence:
    - reference: PMID:42263400
      reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In MPTP-treated male and female mice, hippocampal complement components (C1Q, C3, C3aR) and downstream signalling (p-STAT3, p-P65) were elevated, accompanied by microglial synapse phagocytosis and depressive-like behaviours. Genetic deletion of C3 rescued both MPTP-induced motor and depressive-like behavioural deficits and prevented hippocampal synaptic loss associated with microglial synaptic engulfment."
      explanation: >
        Elevation of hippocampal complement components strongly correlates with microglial
        synaptic phagocytosis and depressive-like behaviors in MPTP mice. C3 deletion
        rescued depressive deficits and prevented synaptic loss, demonstrating causal
        linkage of complement activation to depression in PD models.
  evidence:
  - reference: PMID:42263400
    reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In MPTP-treated male and female mice, hippocampal complement components (C1Q, C3, C3aR) and downstream signalling (p-STAT3, p-P65) were elevated, accompanied by microglial synapse phagocytosis and depressive-like behaviours."
    explanation: >
      MPTP mouse model demonstrates upregulation of complement cascade components in
      hippocampus alongside microglial synaptic phagocytosis and depression-like behaviors,
      establishing the complement pathway as a mechanism driving depression in PD.
  - reference: PMID:42263400
    reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DPD exhibits distinct sex-specific immune signatures, with convergent complement pathway activation driving microglial synaptic pruning and depressive symptoms."
    explanation: >
      Human plasma proteomic analysis from PPMI cohort reveals that depression in PD
      exhibits sex-specific complement pathway dysregulation, establishing complement
      activation as a mechanism contributing to depressive symptoms.
  - reference: PMID:42263400
    reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The antidepressant effect of BoNT/A is mediated through inhibition of the C3-C3aR signalling axis."
    explanation: >
      Mouse model studies demonstrate that complement pathway inhibition (via BoNT/A
      blocking C3-C3aR signaling) alleviates depressive-like symptoms and reduces
      microglial synaptic engulfment, providing mechanistic validation of C3-C3aR
      as a therapeutic target in depression.
- name: Autophagy-Lysosome Pathway Dysfunction
  description: >
    Impairment of the autophagy-lysosome pathway disrupts clearance of misfolded
    proteins including alpha-synuclein. Multiple PD genes (GBA, LRRK2, VPS35,
    ATP13A2) regulate lysosomal function, and their mutations impair protein
    degradation capacity leading to toxic protein accumulation.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: Chaperone-mediated Autophagy
    term:
      id: GO:0061684
      label: chaperone-mediated autophagy
  downstream:
  - target: Alpha-Synuclein Aggregation
    evidence:
    - reference: PMID:31761667
      reference_title: "Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics."
      supports: SUPPORT
      snippet: "α-synuclein, encoded by the SNCA gene, is degraded mainly by the ALP, and mutations/multiplications in SNCA may lead to impairment of chaperone mediated autophagy or other ALP functions."
      explanation: This shows that autophagy-lysosome pathway dysfunction impairs α-synuclein clearance, supporting aggregation downstream.
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:31761667
      reference_title: "Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics."
      supports: SUPPORT
      snippet: "In recent years, multiple lines of evidence from human genetic and molecular studies have highlighted the importance of the autophagy lysosomal pathway (ALP) in Parkinson's disease (PD)."
      explanation: This supports ALP dysfunction as a key PD mechanism contributing to neuronal degeneration.
  evidence:
  - reference: PMID:31761667
    reference_title: "Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics."
    supports: SUPPORT
    snippet: "In recent years, multiple lines of evidence from human genetic and molecular studies have highlighted the importance of the autophagy lysosomal pathway (ALP) in Parkinson's disease (PD). Genes such as GBA and LRRK2, which harbor some of the most common mutations associated with PD, have essential roles in the ALP."
    explanation: This review establishes the genetic basis for autophagy-lysosome dysfunction in PD, identifying key genes and their mechanistic roles.
- name: Gut Microbiome Dysbiosis
  description: >
    Parkinson disease cohorts show reproducible but modest gut microbiome
    shifts, including depletion of short-chain-fatty-acid-producing taxa and
    enrichment of genera linked to mucin or inflammatory biology. In the
    body-first model, dysbiosis is modeled as a plausible upstream trigger or
    modifier of intestinal inflammation and barrier dysfunction, not as an
    established direct cause of alpha-synuclein initiation.
  cell_types:
  - preferred_term: Enteroendocrine Cell
    term:
      id: CL:0000164
      label: enteroendocrine cell
  locations:
  - preferred_term: intestine
    term:
      id: UBERON:0000160
      label: intestine
  downstream:
  - target: Intestinal Inflammation and Barrier Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      PD-associated dysbiosis may promote a pro-inflammatory intestinal state
      and barrier dysfunction, but the direction and necessity of this link
      remain unresolved in humans.
    evidence:
    - reference: PMID:33692356
      reference_title: "Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "This dysbiosis might result in a pro-inflammatory status which could be linked to the recurrent gastrointestinal symptoms affecting PD patients."
      explanation: >
        Cross-cohort microbiome meta-analysis supports a dysbiosis-to-
        inflammation interpretation but phrases the causal link as a possibility.
    - reference: PMID:34220443
      reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "A causal relationship has not been established, but gut dysbiosis is prevalent in PD and may lead to intestinal inflammation and barrier dysfunction."
      explanation: >
        Human marker data support modeling dysbiosis upstream of barrier and
        inflammatory changes while explicitly preserving causal uncertainty.
  evidence:
  - reference: PMID:33692356
    reference_title: "Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found significant alterations in the PD-associated microbiome, which are robust to study-specific technical heterogeneities, although differences in microbiome structure between PD and controls are small."
    explanation: >
      Meta-analysis across ten 16S datasets supports a reproducible
      PD-associated gut microbiome signature, while noting small effect sizes.
  - reference: PMID:36332796
    reference_title: "Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Alterations in the gut microbiome and associated metabolites may contribute to pathogenesis in PD."
    explanation: >
      Review-level evidence supports gut microbiome changes as plausible
      contributors to PD pathogenesis, but not as proven initiators.
- name: Intestinal Inflammation and Barrier Dysfunction
  description: >
    Sporadic Parkinson disease is associated with elevated intestinal
    inflammatory and permeability markers. These changes may create a local
    milieu that increases alpha-synuclein expression or exposes enteric neurons
    to amyloidogenic microbial or dietary compounds, but whether they initiate
    body-first PD or arise secondary to gut autonomic dysfunction remains open.
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Enteric Alpha-Synuclein Seeding
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      Local gut inflammation and barrier leakiness may increase enteric
      alpha-synuclein expression or amyloidogenic exposure, providing a
      permissive setting for enteric alpha-synuclein seeding.
    evidence:
    - reference: PMID:34220443
      reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Gut dysbiosis is common in PD and can result in local inflammatory changes and barrier dysfunction/disruption, which may increase alpha-synuclein expression and facilitate its exposure to amyloidogenic compounds found in the gut, thus possibly contributing to key pathogenic events in PD; prospective evidence is nevertheless scarce"
      explanation: >
        Human marker study discussion supports a plausible route from
        dysbiosis/inflammation/barrier disruption to enteric alpha-synuclein
        seeding but explicitly notes scarce prospective evidence.
  evidence:
  - reference: PMID:34220443
    reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Calprotectin and zonulin are markers of intestinal inflammation and barrier permeability, respectively."
    explanation: >
      Establishes the measured marker interpretation for this intestinal
      inflammation and barrier dysfunction node.
  - reference: PMID:34220443
    reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean calprotectin was higher in PD, both in serum (14.26 mcg/ml ± 4.50 vs. 5.94 mcg/ml ± 3.80, p = 0.0125) and stool (164.54 mcg/g ± 54.19 vs. 56.19 mcg/g ± 35.88, p = 0.0048)."
    explanation: >
      Case-control data support elevated intestinal inflammatory markers in PD.
- name: Enteric Alpha-Synuclein Seeding
  description: >
    In the body-first model, misfolded alpha-synuclein appears first in enteric
    or peripheral autonomic neural tissue and serves as the initiating seed for
    subsequent gut-to-brain spread. Direct causal support comes primarily from
    animal models that seed pathologic alpha-synuclein in the gastrointestinal
    wall.
  cell_types:
  - preferred_term: Enteric Neuron
    term:
      id: CL:0007011
      label: enteric neuron
  locations:
  - preferred_term: enteric nervous system
    term:
      id: UBERON:0002005
      label: enteric nervous system
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  downstream:
  - target: Vagal-Brainstem Alpha-Synuclein Propagation
    causal_link_type: DIRECT
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      Enteric alpha-synuclein seeds can propagate first to vagal brainstem
      nuclei and then to additional brain regions.
    evidence:
    - reference: PMID:31255487
      reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Spread of pathologic α-syn in brain, as assessed by phosphorylation of serine 129 of α-syn, was observed first in the dorsal motor nucleus, then in caudal portions of the hindbrain"
      explanation: >
        Gut-seeded mouse alpha-synuclein pathology first appears in vagal
        brainstem regions, supporting the enteric seeding to vagal propagation
        edge.
    - reference: PMID:39241780
      reference_title: "Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Gut pathology was initially observed, and α-Syn or Tau pathology was subsequently propagated into the DMV or NTS and then to other brain regions."
      explanation: >
        Independent gut-inducible mouse models support propagation from gut
        pathology to vagal brainstem nuclei and then broader brain regions.
  - target: Constipation
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    description: >
      Enteric or autonomic involvement is a plausible contributor to early
      constipation in body-first PD, but this edge remains clinically inferred.
    evidence:
    - reference: PMID:34220443
      reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "most people with sporadic PD develop gastrointestinal symptoms related to decreased transit time, constipation preceding the motor dysfunction with more than a decade in some cases"
      explanation: >
        Supports constipation as an early gastrointestinal manifestation
        compatible with body-first PD, without proving enteric seeding as its
        cause.
  evidence:
  - reference: PMID:31255487
    reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "fibrils were injected into the duodenal and pyloric muscularis layer"
    explanation: >
      The gut-to-brain transmission model experimentally seeds pathologic
      alpha-synuclein in the gastrointestinal wall.
  - reference: PMID:34220443
    reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The coexistence of an amyloidogenic gut microbiota with intestinal inflammation (leading to local overexpression of alpha-synuclein) and altered intestinal barrier permeability (exposing alpha-synuclein to the amyloidogenic xenobiotics) may play a key role in triggering the initial alpha-synuclein conformational changes in some people with sporadic PD"
    explanation: >
      Human review/discussion within the marker study supports enteric
      alpha-synuclein seeding as a plausible but not proven event in some
      sporadic PD cases.
- name: Vagal-Brainstem Alpha-Synuclein Propagation
  description: >
    Pathologic alpha-synuclein seeded in the gastrointestinal wall can propagate
    through vagal connections to the dorsal motor nucleus, nucleus tractus
    solitarius, caudal hindbrain, and ultimately midbrain and forebrain regions.
    Vagotomy experiments provide the strongest causal evidence for this
    body-first conduit.
  locations:
  - preferred_term: vagus nerve
    term:
      id: UBERON:0001759
      label: vagus nerve
  - preferred_term: midbrain
    term:
      id: UBERON:0001891
      label: midbrain
  downstream:
  - target: Alpha-Synuclein Aggregation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - body_first_enteric_alpha_synuclein_model
    intermediate_mechanisms:
    - dorsal motor nucleus and nucleus tractus solitarius involvement
    - caudal hindbrain and higher brain region propagation
    description: >
      Vagal-brainstem propagation links gut-origin pathology to the broader
      central alpha-synuclein aggregation cascade.
    evidence:
    - reference: PMID:31255487
      reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Truncal vagotomy and α-syn deficiency prevented the gut-to-brain spread of α-synucleinopathy and associated neurodegeneration and behavioral deficits."
      explanation: >
        Vagotomy rescue supports the vagus nerve as a required conduit for
        gut-origin alpha-synucleinopathy reaching the brain.
    - reference: PMID:39241780
      reference_title: "Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Truncal vagotomy and α-Syn deficiency significantly inhibited synucleinopathy or tauopathy spreading."
      explanation: >
        Independent gut-inducible mouse data support the same vagal conduit for
        inhibitable synucleinopathy spread.
  evidence:
  - reference: PMID:31255487
    reference_title: "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Analysis of human pathology led Braak to postulate that α-synuclein (α-syn) pathology could spread from the gut to brain via the vagus nerve."
    explanation: >
      Establishes the gut-to-brain vagal propagation hypothesis tested by the
      mouse transmission model.
  - reference: PMID:39241780
    reference_title: "Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "α-Syn and Tau co-pathology can propagate from the gut to the brain, triggering behavioral disorders."
    explanation: >
      Supports gut-to-brain propagation in a gut-inducible transgenic mouse
      system.
- name: Central Alpha-Synuclein Initiation
  description: >
    In the brain-first model, the initial alpha-synuclein pathology begins in
    central sites such as the olfactory bulb or amygdala, then spreads through
    connected brain regions and later to peripheral autonomic structures. This
    node captures the competing central-origin route without asserting that it
    applies to all Parkinson disease.
  locations:
  - preferred_term: olfactory bulb
    term:
      id: UBERON:0002264
      label: olfactory bulb
  - preferred_term: amygdala
    term:
      id: UBERON:0001876
      label: amygdala
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  downstream:
  - target: Alpha-Synuclein Aggregation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - brain_first_central_alpha_synuclein_model
    intermediate_mechanisms:
    - central network propagation from olfactory bulb or amygdala
    description: >
      Central initiation feeds into the broader alpha-synuclein aggregation and
      propagation cascade through connected brain networks.
    evidence:
    - reference: PMID:38519273
      reference_title: "Brain-first vs. body-first Parkinson's disease: An update on recent evidence."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype."
      explanation: >
        Human subtype review supports olfactory bulb or amygdala origin as the
        central initiation route for the brain-first model.
  evidence:
  - reference: PMID:38519273
    reference_title: "Brain-first vs. body-first Parkinson's disease: An update on recent evidence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular imaging studies were generally in agreement with the model, whereas structural imaging studies, such as MRI volumetry, showed conflicting findings."
    explanation: >
      Review-level synthesis supports the brain-first/body-first model while
      noting that not all imaging modalities agree.
  - reference: PMID:32830221
    reference_title: "Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the PDRBD- data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal."
    explanation: >
      Primary PET, MIBG, MRI, and gut-transit imaging evidence supports the
      central-first route by identifying a de novo PD subgroup with primary
      putaminal dopaminergic dysfunction followed by peripheral autonomic loss.
- name: Oxidative Stress
  description: >
    Excessive reactive oxygen species from dopamine metabolism and mitochondrial
    dysfunction causes lipid peroxidation, protein carbonylation, and DNA damage.
    Dopamine auto-oxidation generates toxic quinones that preferentially damage
    substantia nigra neurons.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: ROS Metabolic Process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
  downstream:
  - target: Mitochondrial Dysfunction
  - target: Dopaminergic Neuron Loss
  - target: Alpha-Synuclein Aggregation
  evidence:
  - reference: PMID:37303175
    reference_title: "Oxidative Stress and Dopaminergic Metabolism: A Major PD Pathogenic Mechanism and Basis of Potential Antioxidant Therapies."
    supports: SUPPORT
    snippet: "Reactive oxygen species (ROS)-induced oxidative stress triggers the vicious cycle leading to the degeneration of dopaminergic neurons in the nigra pars compacta."
    explanation: This review directly describes the mechanism by which oxidative stress drives dopaminergic neurodegeneration.
- name: Calcium Dysregulation
  description: >
    Substantia nigra dopaminergic neurons rely on L-type calcium channels (CaV1.3)
    for autonomous pacemaking, making them uniquely vulnerable to calcium-mediated
    toxicity. Disrupted calcium homeostasis in mitochondria, ER, and lysosomes
    contributes to oxidative stress and cell death.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Calcium Ion Homeostasis
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  - preferred_term: Calcium Ion Transport
    term:
      id: GO:0070588
      label: calcium ion transmembrane transport
  downstream:
  - target: Mitochondrial Dysfunction
  - target: Oxidative Stress
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:35339179
    reference_title: "The Role of Voltage-Gated Calcium Channels in Basal Ganglia Neurodegenerative Disorders."
    supports: SUPPORT
    snippet: "Calcium (Ca2+) plays a central role in regulating many cellular processes and influences cell survival."
    explanation: This review establishes the fundamental role of calcium channel dysregulation in PD pathogenesis.
- name: Endoplasmic Reticulum Stress
  description: >
    Accumulation of misfolded proteins in the ER activates the unfolded protein
    response (UPR). Chronic ER stress overwhelms protective mechanisms, triggering
    apoptotic pathways. Alpha-synuclein aggregates and GBA mutations directly
    impair ER function.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: ER Stress Response
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
  - preferred_term: Unfolded Protein Response
    term:
      id: GO:0030968
      label: endoplasmic reticulum unfolded protein response
  downstream:
  - target: Autophagy-Lysosome Pathway Dysfunction
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:38026955
    reference_title: "Strategies targeting endoplasmic reticulum stress to improve Parkinson's disease."
    supports: SUPPORT
    snippet: "Accumulating evidence shows that endoplasmic reticulum (ER) stress occurring in the SNpc DA neurons is an early event in the development of PD."
    explanation: This review establishes ER stress as an early and central event in PD pathogenesis.
- name: Synaptic Dysfunction
  description: >
    Impaired synaptic vesicle recycling, particularly defects in clathrin-mediated
    endocytosis, represents an early feature of PD. Multiple PD genes (DNAJC6,
    SYNJ1, LRRK2) regulate synaptic vesicle trafficking, and their dysfunction
    leads to synaptic failure before overt neurodegeneration.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Synaptic Vesicle Cycle
    term:
      id: GO:0099504
      label: synaptic vesicle cycle
  - preferred_term: Synaptic Vesicle Endocytosis
    term:
      id: GO:0048488
      label: synaptic vesicle endocytosis
  downstream:
  - target: Dopaminergic Neuron Loss
  - target: Alpha-Synuclein Aggregation
  evidence:
  - reference: PMID:38595283
    reference_title: "Dysfunction of synaptic endocytic trafficking in Parkinson's disease."
    supports: SUPPORT
    snippet: "Notably, several of these genes are linked to the synaptic vesicle recycling process, particularly the clathrin-mediated endocytosis pathway. This suggests that impaired synaptic vesicle recycling might represent an early feature of Parkinson's disease"
    explanation: Establishes synaptic vesicle endocytosis dysfunction as an early feature of PD.
- name: Iron Accumulation and Ferroptosis
  description: >
    Abnormal iron deposition in the substantia nigra promotes ferroptosis, an
    iron-dependent form of cell death characterized by lipid peroxidation. Iron
    catalyzes Fenton reactions generating hydroxyl radicals, and dysregulated
    iron metabolism contributes to oxidative damage.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Iron Ion Homeostasis
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
  - preferred_term: Ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
  downstream:
  - target: Oxidative Stress
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:39218077
    reference_title: "Ferroptosis in Parkinson's disease -- The iron-related degenerative disease."
    supports: SUPPORT
    snippet: "Parkinson's disease (PD) is a prevalent and advancing age-related neurodegenerative disorder, distinguished by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Iron regional deposit in SNpc is a significant pathological characteristic of PD."
    explanation: This review establishes iron accumulation as a significant pathological characteristic and mechanistic driver of PD.
- name: Blood-Brain Barrier Dysfunction
  description: >
    Altered tight junction proteins, transporter dysfunction, and alpha-synuclein
    accumulation compromise BBB integrity. BBB breakdown allows infiltration of
    peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.
  cell_types:
  - preferred_term: Brain Endothelial Cell
    term:
      id: CL:2000044
      label: brain microvascular endothelial cell
  - preferred_term: Pericyte
    term:
      id: CL:0000669
      label: pericyte
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: BBB Maintenance
    term:
      id: GO:0035633
      label: maintenance of blood-brain barrier
  - preferred_term: Vascular Permeability
    term:
      id: GO:0043114
      label: regulation of vascular permeability
  downstream:
  - target: Neuroinflammation
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:39075566
    reference_title: "Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy."
    supports: SUPPORT
    snippet: "There is increasing evidence for blood-brain barrier (BBB) alterations in Parkinson's disease (PD), the second most common neurodegenerative disorder with rapidly rising prevalence."
    explanation: This comprehensive 2024 review establishes BBB dysfunction as an emerging mechanism in PD pathogenesis.
- name: Metabolic Dysfunction and Weight Loss
  description: >
    Parkinson disease is associated with progressive weight loss and metabolic dysregulation
    through multiple interacting mechanisms. Reduced metabolic rate, dysregulated appetite-regulating
    hormones (leptin, ghrelin, GLP-1), gastrointestinal dysfunction, cognitive decline affecting
    appetite awareness, dopaminergic-medication effects, and dopamine-dependent regulation of
    feeding behavior all contribute to systemic metabolic failure and weight loss. Weight loss
    occurs in a substantial fraction of PD patients and exerts significant morbidity and mortality,
    yet mechanistic understanding remains incomplete.
  biological_processes:
  - preferred_term: Metabolic process
    term:
      id: GO:0008152
      label: metabolic process
  downstream:
  - target: Weight Loss and Nutritional Decline
    causal_link_type: DIRECT
    description: >
      Metabolic dysregulation, reduced energy expenditure, neuroendocrine hormone
      imbalances, and gastrointestinal dysfunction converge to cause progressive
      weight loss and nutritional decline in PD.
    evidence:
    - reference: PMID:41781031
      reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Emerging research highlights the role of metabolic regulation, neuroendocrine signaling, pharmacologic treatment, cognitive decline, gastrointestinal dysfunction, and brain stimulation in shaping weight trajectories in PD."
      explanation: >
        This review identifies multiple converging pathways that shape weight loss
        in PD, directly supporting metabolic dysfunction as a driver of weight loss.
  evidence:
  - reference: PMID:41781031
    reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood. This limited mechanistic insight has left few treatment options for weight loss in PD."
    explanation: >
      This 2026 review establishes weight loss as a significant, mechanistically
      complex, and undertreated symptom of Parkinson disease, establishing the
      rationale for a dedicated metabolic dysfunction mechanism node.
phenotypes:
- name: Resting Tremor
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Classic "pill-rolling" tremor at rest
  phenotype_term:
    preferred_term: Resting Tremor
    term:
      id: HP:0002322
      label: Resting tremor
  evidence:
  - reference: PMID:17955331
    reference_title: "The Rotterdam Study: objectives and design update."
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This identifies resting tremor as a cardinal sign used to detect parkinsonism, supporting it as a core PD phenotype.
- name: Bradykinesia
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Slowness of movement, required for diagnosis
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: PMID:17955331
    reference_title: "The Rotterdam Study: objectives and design update."
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This lists bradykinesia among the cardinal signs of parkinsonism, supporting its central role in PD.
- name: Rigidity
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Cogwheel or lead-pipe rigidity
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  evidence:
  - reference: PMID:17955331
    reference_title: "The Rotterdam Study: objectives and design update."
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This confirms rigidity as a cardinal sign of parkinsonism relevant to PD.
- name: Postural Instability
  category: Neurological
  frequency: FREQUENT
  notes: Develops in later disease stages
  phenotype_term:
    preferred_term: Postural Instability
    term:
      id: HP:0002172
      label: Postural instability
  evidence:
  - reference: PMID:17955331
    reference_title: "The Rotterdam Study: objectives and design update."
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This supports postural instability as a cardinal parkinsonian sign captured in PD assessments.
- name: Hyposmia
  category: Sensory
  frequency: FREQUENT
  notes: Often precedes motor symptoms by years
  phenotype_term:
    preferred_term: Hyposmia
    term:
      id: HP:0004409
      label: Hyposmia
  evidence:
  - reference: PMID:24136244
    reference_title: "Hyposmia: a possible biomarker of Parkinson's disease."
    supports: SUPPORT
    snippet: "Hyposmia, identified as reduced sensitivity to odor, is a common non-motor symptom of Parkinson's disease (PD) that antedates the typical motor symptoms by several years. It occurs in ∼90% of early-stage cases of PD."
    explanation: This establishes hyposmia as a highly prevalent prodromal symptom that precedes motor symptoms, supporting its importance as an early marker of PD.
- name: Constipation
  category: Gastrointestinal
  frequency: FREQUENT
  notes: Common non-motor symptom
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:7845407
    reference_title: "Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation."
    supports: SUPPORT
    snippet: "We investigated the role of anorectal manometry in evaluating constipation and anorectal function in 15 patients with Parkinson's disease (PD) and compared results with those of 9 patients with idiopathic constipation (IC) and 8 control (C) subjects."
    explanation: This study directly evaluates constipation in PD patients, supporting constipation as a common non-motor symptom.
- name: Depression
  category: Psychiatric
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:41301797
    reference_title: "Non-Motor Symptoms as Markers of Disease Severity in Parkinson's Disease: Associations Between Constipation, Depression, REM Sleep Behavior Disorder, and Motor Impairment."
    supports: SUPPORT
    snippet: "Depressive symptoms were similar across groups, but in prodromal PD, higher GDS scores were associated with worse UPDRS III scores (p = 0.02), as well as higher freezing and fall scores."
    explanation: This indicates depressive symptoms are present and clinically relevant in PD, supporting depression as a non-motor phenotype.
stages:
- name: "Stage 1: Unilateral Disease"
  description: >
    Symptoms are present on one side of the body only. Mild unilateral involvement
    with minimal or no functional impairment. Patients may exhibit resting tremor,
    rigidity, or bradykinesia on one limb or side. Daily activities are not
    significantly affected.
  evidence:
  - reference: PMID:27918765
    supports: SUPPORT
    snippet: "the Hoehn and Yahr scale, with the lowest grade indicating unilateral involvement with minimal or no functional impairment"
    explanation: This describes Stage 1 (the lowest grade) as unilateral involvement with minimal or no functional impairment.
  - reference: PMID:34461264
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Clinical findings indicate that LID typically only occurs following the progression of PD motor symptoms from the unilateral (Hoehn and Yahr (HY) Stage I) to the bilateral stage (HY Stage II)."
    explanation: This identifies Stage I as the unilateral phase of PD motor symptoms.
  notes: >
    Original Hoehn and Yahr staging scale from 1967 (PMID:6067254). A modified
    scale with 0.5 increments (Stages 1.5, 2.5) has been widely adopted but
    lacks formal clinimetric validation.
- name: "Stage 2: Bilateral Disease Without Balance Impairment"
  description: >
    Symptoms are present on both sides of the body or at the midline. Bilateral
    involvement without impairment of balance. Patients show bilateral tremor,
    rigidity, and bradykinesia but maintain normal postural reflexes and physical
    independence.
  evidence:
  - reference: PMID:34461264
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Clinical findings indicate that LID typically only occurs following the progression of PD motor symptoms from the unilateral (Hoehn and Yahr (HY) Stage I) to the bilateral stage (HY Stage II)."
    explanation: This identifies Stage II as the bilateral stage of PD motor symptom progression.
  - reference: PMID:15372591
    supports: SUPPORT
    snippet: "the scale fulfills at least some criteria for reliability and validity, especially for the midranges of the scale (Stages 2-4)."
    explanation: The MDS Task Force report validates the reliability of midrange stages (2-4) of the Hoehn and Yahr scale.
- name: "Stage 3: Bilateral Disease With Postural Instability"
  description: >
    Mild to moderate bilateral disease with early postural instability. The first
    sign of impaired righting reflexes appears. Patients remain physically
    independent in daily activities but have clinically evident balance impairment.
  evidence:
  - reference: PMID:20181069
    supports: SUPPORT
    snippet: "The modified Hoehn and Yahr scale was 3: mild to moderate bilateral disease; some postural instability; physically independent."
    explanation: This directly defines Stage 3 as mild to moderate bilateral disease with some postural instability while remaining physically independent.
  - reference: PMID:15372591
    supports: SUPPORT
    snippet: "Because the HY scale is weighted heavily toward postural instability as the primary index of disease severity, it does not capture completely impairments or disability from other motor features of PD and gives no information on nonmotor problems."
    explanation: This highlights that the Hoehn and Yahr scale weights postural instability as a primary severity index, providing context for why balance impairment becomes central at Stage 3.
- name: "Stage 4: Severe Disability, Still Ambulatory"
  description: >
    Fully developed, severely disabling disease. Patients remain ambulatory but
    have marked loss of independence in daily activities. More than half require
    assistance with most activities of daily living, despite retained ability to
    complete walk-based assessments.
  evidence:
  - reference: PMID:34125001
    supports: SUPPORT
    snippet: "Her disease severity was classified as Hoehn and Yahr stage 4. The unified Parkinson's disease rating scale (UPDRS) part 3, 10-m walk test (10MWT), timed up-and-go test (TUG), Berg balance scale (BBS), and 30-s chair stand test (30-s CST) were used for assessment before and after intervention."
    explanation: This stage 4 case report shows that advanced patients can remain ambulatory enough to perform walk-based assessments despite severe motor impairment.
  - reference: PMID:40162911
    supports: SUPPORT
    snippet: "In the H-Y Stage 4 group, more than half of the patients required assistance with most ADLs, except feeding and bowel control."
    explanation: This directly supports substantial dependence in daily activities as a defining functional feature of Stage 4 disease.
- name: "Stage 5: Wheelchair-Bound or Bedridden"
  description: >
    Patient is confined to wheelchair or bedridden unless aided. Complete
    dependence on caregivers for all activities. Represents the most severe
    stage of motor disability in Parkinson's disease.
  evidence:
  - reference: PMID:27918765
    supports: SUPPORT
    snippet: "the highest grade defining patients with complete confinement to wheelchair or bed."
    explanation: This directly defines Stage 5 (the highest grade) as complete confinement to wheelchair or bed.
genetic:
- name: SNCA
  association: Causative
  notes: Alpha-synuclein gene, autosomal dominant forms
  evidence:
  - reference: PMID:9197268
    reference_title: "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease."
    supports: SUPPORT
    snippet: "A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype."
    explanation: This landmark 1997 Science paper identified the first SNCA mutations in familial PD with autosomal dominant inheritance, establishing SNCA as a causative gene for Parkinson's disease.
  - reference: CGGV:assertion_d21593ae-ed10-4442-8167-24f96f917302-2022-05-03T134931.425Z
    reference_title: "SNCA / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SNCA | HGNC:11138 | Parkinson disease | MONDO:0005180 | AD | Definitive"
    explanation: ClinGen classifies the SNCA-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: LRRK2
  association: Risk Factor
  notes: Most common genetic cause of late-onset PD
  evidence:
  - reference: PMID:19945904
    reference_title: "Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review."
    supports: SUPPORT
    snippet: "The LRRK2 G2019S mutation is the most frequent known cause of familial and sporadic Parkinson's disease."
    explanation: This systematic review establishes that LRRK2 G2019S is the most common genetic cause of both familial and sporadic PD, supporting its role as the major genetic risk factor.
  - reference: CGGV:assertion_2728e13a-b95a-4c55-8cba-082260094ecd-2021-05-03T160000.000Z
    reference_title: "LRRK2 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "LRRK2 | HGNC:18618 | Parkinson disease | MONDO:0005180 | AD | Definitive"
    explanation: ClinGen classifies the LRRK2-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: GBA
  association: Risk Factor
  notes: Glucocerebrosidase, major genetic risk factor
  evidence:
  - reference: PMID:30097731
    reference_title: "The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions."
    supports: SUPPORT
    snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
    explanation: This identifies GBA as a genetic risk locus shared with PD, supporting its role as a PD risk factor.
- name: PARK2
  association: Causative
  notes: Parkin gene, early-onset autosomal recessive
  evidence:
  - reference: PMID:25611507
    reference_title: "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease."
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This establishes Parkin (PARK2) as a gene mutated in autosomal recessive parkinsonism, supporting its causative role.
- name: PINK1
  association: Causative
  notes: Mitochondrial kinase, autosomal recessive
  evidence:
  - reference: PMID:25611507
    reference_title: "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease."
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This identifies PINK1 mutations in autosomal recessive parkinsonism, supporting its causative role in PD.
  - reference: CGGV:assertion_1999e6c4-eb15-438a-a4ea-98989112dcbb-2023-01-18T190000.000Z
    reference_title: "PINK1 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PINK1 | HGNC:14581 | Parkinson disease | MONDO:0005180 | AR | Definitive"
    explanation: ClinGen classifies the PINK1-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: GBA1
  gene_term:
    preferred_term: GBA1
    term:
      id: hgnc:4177
      label: GBA
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_9201c03f-10de-447c-9b84-194f14b549b6-2022-05-03T134810.206Z
    reference_title: "GBA1 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GBA1 | HGNC:4177 | Parkinson disease | MONDO:0005180 | AD | Definitive"
    explanation: ClinGen classifies the GBA1-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: PARK7
  gene_term:
    preferred_term: PARK7
    term:
      id: hgnc:16369
      label: PARK7
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_d79439d2-844b-4ba6-aceb-e6b179eaaa01-2022-06-27T160000.000Z
    reference_title: "PARK7 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PARK7 | HGNC:16369 | Parkinson disease | MONDO:0005180 | AR | Definitive"
    explanation: ClinGen classifies the PARK7-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: PRKN
  gene_term:
    preferred_term: PRKN
    term:
      id: hgnc:8607
      label: PRKN
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_6b39c4a0-f6bd-4afc-b2a7-f234eab5a667-2023-01-18T190000.000Z
    reference_title: "PRKN / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PRKN | HGNC:8607 | Parkinson disease | MONDO:0005180 | AR | Definitive"
    explanation: ClinGen classifies the PRKN-Parkinson disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: VPS35
  gene_term:
    preferred_term: VPS35
    term:
      id: hgnc:13487
      label: VPS35
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_b0e546d6-8a44-4e9d-83aa-f781ec4ec166-2021-11-03T134517.796Z
    reference_title: "VPS35 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "VPS35 | HGNC:13487 | Parkinson disease | MONDO:0005180 | AD | Definitive"
    explanation: ClinGen classifies the VPS35-Parkinson disease gene-disease relationship as definitive with autosomal dominant inheritance.
environmental:
- name: Pesticide Exposure
  notes: Rotenone and paraquat linked to increased risk
  evidence:
  - reference: PMID:15177059
    reference_title: "Occupational and environmental risk factors for Parkinson's disease."
    supports: SUPPORT
    snippet: "there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."
    explanation: This review supports pesticide exposure as an environmental factor influencing PD risk.
- name: Rural Living
  notes: Associated with pesticide/herbicide exposure
  evidence:
  - reference: PMID:15177059
    reference_title: "Occupational and environmental risk factors for Parkinson's disease."
    supports: PARTIAL
    snippet: "While clear links to rural living, dietary factors, exposure to metals, head injury, and exposure to infectious diseases during childhood have not been established, there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."
    explanation: This review notes that clear links to rural living are not established, indicating mixed evidence for this risk factor.
- name: Head Trauma
  notes: Possible risk factor
  evidence:
  - reference: PMID:36781627
    reference_title: "Traumatic brain injury and risk of Parkinson's disease: a meta-analysis."
    supports: SUPPORT
    snippet: "The risk ratio of TBI among PD and controls by a combination of 15 studies using a random-effect model was 1.48 (95% CI 1.22-1.74)."
    explanation: This meta-analysis supports head trauma (TBI) as a risk factor for developing PD.
treatments:
- name: Levodopa/Carbidopa
  description: Gold standard treatment, replaces dopamine precursor.
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies L-Dopa as a core pharmacotherapy for PD motor symptoms.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levodopa
      term:
        id: CHEBI:15765
        label: L-dopa
    - preferred_term: carbidopa
      term:
        id: CHEBI:3395
        label: carbidopa
  target_mechanisms:
  - target: Striatal Dopamine Deficiency
    treatment_effect: RESTORES
    description: Levodopa supplies dopamine precursor to partially restore dopaminergic signaling in dopamine-depleted striatal circuits.
- name: Dopamine Agonists
  description: Directly stimulate dopamine receptors.
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies dopamine agonists as part of standard pharmacotherapy for PD.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Striatal Dopamine Deficiency
    treatment_effect: BYPASSES
    description: Dopamine agonists bypass reduced endogenous dopamine by directly stimulating dopamine receptors in downstream circuits.
- name: MAO-B Inhibitors
  description: Prevent dopamine breakdown (selegiline, rasagiline).
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists MAO-B inhibitors among standard PD pharmacotherapies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Striatal Dopamine Deficiency
    treatment_effect: MODULATES
    description: MAO-B inhibitors prolong dopamine signaling by reducing dopamine breakdown.
- name: COMT Inhibitors
  description: Extend levodopa duration (entacapone).
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists COMT inhibitors among standard PD pharmacotherapies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Striatal Dopamine Deficiency
    treatment_effect: MODULATES
    description: COMT inhibitors extend levodopa-derived dopaminergic signaling and indirectly modulate striatal dopamine deficiency.
- name: Deep Brain Stimulation
  description: Surgical therapy for advanced motor fluctuations.
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies deep brain stimulation as a standard symptomatic therapy for PD.
  treatment_term:
    preferred_term: deep brain stimulation
    term:
      id: MAXO:0000943
      label: deep brain stimulation
  target_mechanisms:
  - target: Basal Ganglia Circuit Dysfunction
    treatment_effect: MODULATES
    description: DBS modulates abnormal basal ganglia motor circuit activity rather than acting upstream on dopaminergic neuron loss.
- name: Physical Therapy
  description: Maintains mobility and reduces fall risk.
  evidence:
  - reference: PMID:27577098
    reference_title: "Current and experimental treatments of Parkinson disease: A guide for neuroscientists."
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists physiotherapy as part of symptomatic treatment for PD.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  target_mechanisms:
  - target: Basal Ganglia Circuit Dysfunction
    treatment_effect: BYPASSES
    description: Physical therapy uses exercise, cueing, and compensation to work around basal ganglia motor circuit dysfunction.
- name: Botulinum Neurotoxin A (BoNT/A) for Depression
  description: >
    Botulinum toxin type A alleviates depression in Parkinson's disease by inhibiting
    the complement C3-C3aR signaling axis and reducing microglial synaptic phagocytosis.
    This represents a novel complement-targeted approach to managing depression as a
    non-motor symptom in PD, distinct from BoNT/A's canonical motor symptom applications.
  evidence:
  - reference: PMID:42263400
    reference_title: "The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "BoNT/A treatment alleviated depressive-like behaviours and reduced microglial synaptic engulfment in an MPTP model; these therapeutic effects were abolished in C3-/- and C3aR-/- mice."
    explanation: >
      Mouse PD model demonstrates that BoNT/A alleviates depression-like behavior through
      inhibition of the C3-C3aR complement axis, preventing microglial synaptic engulfment
      and protecting against synapse loss in the hippocampus.
  treatment_term:
    preferred_term: botulinum toxin type A therapy
    term:
      id: MAXO:0009016
      label: botulinum toxin type A therapy
  target_mechanisms:
  - target: Complement C3-C3aR Activation in Depression
    treatment_effect: INHIBITS
    description: >
      BoNT/A suppresses complement C3-C3aR signaling through modulation of microglial
      phagocytosis-related functions, reducing microglial activation and synaptic
      phagocytosis, thereby alleviating depression-like symptoms in PD models.
datasets:
# Parkinson's Disease Gut Microbiome Studies
- accession: sra:PRJNA834801
  title: Large-scale metagenomics of Parkinson's disease gut microbiome
  description: >-
    Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC)
    with over 30% of species, genes and pathways showing altered abundances
    in PD. Identified polymicrobial clusters and competitive relationships.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
  - preferred_term: fecal sample
    term:
      id: OBI:0002503
      label: feces specimen
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - Parkinson's disease
  - healthy controls
  publication: PMID:36357667
  notes: Nature Communications 2022 - largest PD metagenomics to date
  evidence:
  - reference: PMID:37449597
    reference_title: "Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease."
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: sra:PRJNA782492
  title: Multi-omics analysis of PD gut microbiome gene expression
  description: >-
    Integrated metagenomics and metatranscriptomics analyzing microbiome gene
    co-expression networks in Parkinson's disease. Observed significant
    depletion of hub genes in PD patients.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
  - preferred_term: fecal sample
    term:
      id: OBI:0002503
      label: feces specimen
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - Parkinson's disease
  - healthy controls
  notes: npj Biofilms and Microbiomes 2025 - multi-omics approach
  evidence:
  - reference: PMID:37449597
    reference_title: "Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease."
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: sra:PRJNA808166
  title: Longitudinal gut microbiome in Parkinson's disease
  description: >-
    Longitudinal study investigating gut microbiome changes in PD patients
    and impact of device-assisted therapies. Tracks microbiome alterations
    with disease progression.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  sample_types:
  - preferred_term: fecal sample
    term:
      id: OBI:0002503
      label: feces specimen
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - Parkinson's disease baseline
  - Parkinson's disease follow-up
  notes: Frontiers Aging Neuroscience 2022 - longitudinal design
  evidence:
  - reference: PMID:37449597
    reference_title: "Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease."
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: sra:PRJNA530401
  title: PD gut microbiome meta-analysis cohort
  description: >-
    Metagenomic sequencing data from PD patients and controls contributing
    to cross-cohort meta-analyses. Identified alterations linked to
    intestinal inflammation including reduced butyrate producers.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
  - preferred_term: fecal sample
    term:
      id: OBI:0002503
      label: feces specimen
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - Parkinson's disease
  - healthy controls
  notes: npj Parkinson's Disease 2021 - meta-analysis contributing cohort
  evidence:
  - reference: PMID:37449597
    reference_title: "Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease."
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: metabolights:MTBLS2266
  title: Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease
  description: >-
    LC-MS sebum metabolomics in Parkinson's disease, including drug-naive and
    medicated cohorts, compared with well-matched controls to identify lipid
    pathway alterations.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METABOLOMICS
  sample_count: 274
  conditions:
  - Parkinson's disease
  - drug-naive Parkinson's disease
  - medicated Parkinson's disease
  - healthy controls
  publication: PMID:33707447
  findings:
  - statement: Sebum metabolomics in PD shows alterations in lipid metabolism pathways, including the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis.
    evidence:
    - reference: metabolights:MTBLS2266
      supports: SUPPORT
      snippet: "Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis."
      explanation: The dataset description reports lipid pathway alterations detected in sebum metabolomics for PD.
  - statement: LC-MS profiling of 274 participants detected metabolites predictive of PD phenotype.
    evidence:
    - reference: metabolights:MTBLS2266
      supports: SUPPORT
      snippet: "We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype."
      explanation: The dataset description specifies LC-MS profiling and the PD/control cohort sizes.
  evidence:
  - reference: metabolights:MTBLS2266
    supports: SUPPORT
    snippet: "Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid."
    explanation: Establishes that the dataset focuses on PD sebum metabolomics.
  notes: Metabolomics profiling of sebum as a non-invasive biofluid for PD.

- accession: metabolights:MTBLS10743
  title: Metabolomic Changes in Idiopathic and GBA1 Parkinson’s Disease
  description: >-
    Mass spectrometry metabolomics comparing idiopathic Parkinson's disease and
    GBA1-associated Parkinson's disease cohorts with controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METABOLOMICS
  conditions:
  - idiopathic Parkinson's disease
  - GBA1-associated Parkinson's disease
  - healthy controls
  findings:
  - statement: Metabolomic signatures differ between GBA1-PD and idiopathic PD in sebum and serum with good specificity and sensitivity.
    evidence:
    - reference: metabolights:MTBLS10743
      supports: SUPPORT
      snippet: "Differences in metabolomic signatures were seen between ... GBA1-PD and iPD in sebum and serum with good specificity and sensitivity."
      explanation: The dataset description reports discriminative metabolomic signatures between GBA1-PD and idiopathic PD.
  - statement: Serum pathways implicated include sphingolipid metabolism, amino sugar metabolism and amino acid pathways, while sebum features are hypothesised to be lipid degradation products.
    evidence:
    - reference: metabolights:MTBLS10743
      supports: SUPPORT
      snippet: "Significant pathways in serum included sphingolipid metabolism, amino sugar metabolism and amino acid pathways, whereas significant features between groups in sebum are hypothesised to be lipid degradation products."
      explanation: The dataset description lists pathway-level differences in serum and hypothesized lipid degradation products in sebum.
  evidence:
  - reference: metabolights:MTBLS10743
    supports: SUPPORT
    snippet: "Here, we use mass spectrometry based metabolomics to analyse serum and sebum samples from 50 genotyped participants and find differences in lipid and sugar regulation, oxidative stress and the production of amino acids and neurotransmitters which distinguish ... GBA1-PD from iPD."
    explanation: Establishes the dataset's serum and sebum metabolomics design distinguishing GBA1-PD from idiopathic PD.
  notes: Preprint dataset describing metabolic changes in idiopathic vs GBA1 PD.

# CELLxGENE - Multi-region single nucleus PD atlas
- accession: "cellxgene:d5d0df8f-4eee-49d8-a221-a288f50a1590"
  title: A multi-region single nucleus transcriptomic atlas of Parkinson's disease
  description: >-
    Single-nucleus RNA-seq atlas of Parkinson's disease spanning multiple brain
    regions, providing cell-type-resolved transcriptomic profiles of dopaminergic
    neurons and glial populations in PD and healthy controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_types:
  - preferred_term: brain tissue
    tissue_term:
      preferred_term: brain
      term:
        id: UBERON:0000955
        label: brain
  conditions:
  - Parkinson's disease
  - healthy controls
  publication: PMID:39317733
  notes: CZI CELLxGENE collection. DOI 10.1038/s41597-024-04117-y. Multi-region snRNA-seq atlas enabling virtual cell model training on PD-relevant cell states.

discussions:
- discussion_id: gap_pd_microbiome_causal_direction_body_first
  prompt: >-
    In body-first Parkinson disease, are gut microbiome dysbiosis and
    intestinal barrier/inflammatory changes causal triggers for enteric
    alpha-synuclein seeding, modifiers that amplify an already initiated
    synucleinopathy, or secondary consequences of autonomic gut dysfunction?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Gut Microbiome Dysbiosis
  - pathophysiology#Intestinal Inflammation and Barrier Dysfunction
  - pathophysiology#Enteric Alpha-Synuclein Seeding
  - pathophysiology#Vagal-Brainstem Alpha-Synuclein Propagation
  rationale: >-
    Cross-sectional human studies support PD-associated dysbiosis and elevated
    intestinal inflammatory/permeability markers, while animal studies support
    gut-to-brain alpha-synuclein propagation through the vagus nerve. The
    unresolved step is temporal and causal: whether dysbiosis or barrier
    dysfunction initiates enteric alpha-synuclein misfolding in humans, merely
    accelerates propagation, or appears after autonomic denervation has already
    altered gut physiology.
  proposed_experiments:
  - experiment_id: exp_pd_prodromal_microbiome_barrier_alpha_syn_longitudinal_cohort
    name: Prodromal microbiome-barrier alpha-synuclein longitudinal cohort
    description: >-
      Follow iRBD-, constipation-, and hyposmia-enriched prodromal cohorts with
      serial stool metagenomics, SCFA/metabolite profiling, fecal and serum
      calprotectin/zonulin, autonomic imaging, and standardized enteric
      alpha-synuclein biopsy assays before motor conversion.
    experiment_type:
      preferred_term: longitudinal prodromal multi-omics cohort study
    readouts:
    - name: Microbiome dysbiosis trajectory
      target: pathophysiology#Gut Microbiome Dysbiosis
      description: >
        Determine whether reproducible microbiome shifts precede, track with,
        or follow enteric alpha-synuclein and autonomic biomarker changes.
      assays:
      - preferred_term: shotgun metagenomic sequencing
      - preferred_term: fecal metabolomics
      direction: POSITIVE
    - name: Intestinal inflammation and barrier trajectory
      target: pathophysiology#Intestinal Inflammation and Barrier Dysfunction
      description: >
        Measure whether inflammatory and permeability markers rise before
        enteric alpha-synuclein detection and clinical conversion.
      assays:
      - preferred_term: calprotectin assay
      - preferred_term: zonulin assay
      direction: POSITIVE
    - name: Enteric alpha-synuclein seeding
      target: pathophysiology#Enteric Alpha-Synuclein Seeding
      description: >
        Track phosphorylated or aggregated alpha-synuclein in standardized
        enteric biopsies as a candidate initiating event.
      assays:
      - preferred_term: immunohistochemistry
      - preferred_term: alpha-synuclein seed amplification assay
      direction: POSITIVE
    decision_criterion: >-
      Microbiome and barrier changes would support a trigger model only if they
      reproducibly precede enteric alpha-synuclein positivity and autonomic
      denervation in converters; changes that follow autonomic dysfunction would
      support a consequence or modifier model.
    would_support:
    - pathophysiology#Gut Microbiome Dysbiosis
    - pathophysiology#Intestinal Inflammation and Barrier Dysfunction
    - pathophysiology#Enteric Alpha-Synuclein Seeding
  evidence:
  - reference: PMID:34220443
    reference_title: "Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A causal relationship has not been established, but gut dysbiosis is prevalent in PD and may lead to intestinal inflammation and barrier dysfunction."
    explanation: >-
      The human marker study states the core causal-direction uncertainty
      motivating this knowledge gap.
  - reference: PMID:36332796
    reference_title: "Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, it remains unclear how these mechanisms relate to sporadic PD, a more common form of PD."
    explanation: >-
      Review-level synthesis highlights uncertainty about how gut-related
      mechanisms map onto sporadic PD pathogenesis.
- discussion_id: gap_pd_variant_specific_isogenic_hpsc_mechanisms
  prompt: >-
    Which Parkinson disease risk and causal variants produce convergent
    dopaminergic-neuron mechanisms in a controlled human genetic background,
    and which phenotypes are variant-specific, modifier-dependent, or culture
    artifacts?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Dopaminergic Neuron Loss
  - pathophysiology#Alpha-Synuclein Aggregation
  - pathophysiology#Mitochondrial Dysfunction
  - pathophysiology#Autophagy-Lysosome Pathway Dysfunction
  rationale: >-
    Patient-derived iPSC comparisons are powerful but confounded by background
    genetic variation. Large WGS-QC'd isogenic hPSC panels, differentiated into
    midbrain dopaminergic neurons and phenotyped with imaging and sequencing,
    can separate variant-specific causal mechanisms from shared downstream
    neurodegenerative states.
  proposed_experiments:
  - experiment_id: exp_pd_automated_isogenic_hpsc_variant_panel
    name: Automated isogenic hPSC Parkinson variant panel
    description: >-
      Generate or extend a WGS-QC'd isogenic hPSC panel carrying high-risk or
      causal Parkinson disease alleles, differentiate lines into midbrain
      dopaminergic neurons, and benchmark variant-specific effects on
      alpha-synuclein handling, mitochondrial state, lysosomal function, and
      dopaminergic-neuron survival.
    experiment_type:
      preferred_term: high-throughput isogenic stem-cell perturbation experiment
    model_systems:
    - name: Genome-edited hPSC-derived midbrain dopaminergic neuron panel
      description: >-
        Isogenic human pluripotent stem cell collection carrying Parkinson
        disease variants, differentiated into disease-relevant dopaminergic
        neurons for mechanism-resolved phenotyping.
      experimental_model_type: IPSC_DERIVED_MODEL
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
      cell_types:
      - preferred_term: midbrain dopaminergic neuron
        term:
          id: CL:0000700
          label: dopaminergic neuron
      publication: PMID:38405931
      notes: >-
        Designed to be compatible with automated hPSC genome-engineering and
        clonal QC workflows such as ATTIS-style high-throughput line generation.
    perturbations:
    - name: Parkinson disease variant editing
      target: pathophysiology#Dopaminergic Neuron Loss
      description: >
        Introduce or compare causal and high-risk Parkinson alleles in a shared
        genetic background.
      genes:
      - preferred_term: SNCA
        term:
          id: hgnc:11138
          label: SNCA
      - preferred_term: LRRK2
        term:
          id: hgnc:18618
          label: LRRK2
      - preferred_term: GBA1
        term:
          id: hgnc:4177
          label: GBA
      - preferred_term: PINK1
        term:
          id: hgnc:14581
          label: PINK1
      - preferred_term: PRKN
        term:
          id: hgnc:8607
          label: PRKN
    - name: Prime-editing generation or correction
      target: gene#LRRK2
      description: >
        Use prime editing or correction to create reciprocal disease and rescue
        alleles where feasible.
      genes:
      - preferred_term: LRRK2
        term:
          id: hgnc:18618
          label: LRRK2
    readouts:
    - name: Alpha-synuclein aggregation burden
      target: pathophysiology#Alpha-Synuclein Aggregation
      description: >
        High-content imaging and biochemical readouts of alpha-synuclein
        accumulation in differentiated dopaminergic neurons.
      assays:
      - preferred_term: high-content imaging
      - preferred_term: immunocytochemistry
      direction: POSITIVE
    - name: Mitochondrial dysfunction
      target: pathophysiology#Mitochondrial Dysfunction
      description: >
        Mitochondrial respiration, membrane-potential, and stress-state
        measurements across edited variants and corrected controls.
      biological_processes:
      - preferred_term: mitochondrial organization
        term:
          id: GO:0007005
          label: mitochondrion organization
      assays:
      - preferred_term: mitochondrial respiration assay
      direction: NEGATIVE
    - name: Autophagy-lysosome pathway dysfunction
      target: pathophysiology#Autophagy-Lysosome Pathway Dysfunction
      description: >
        Lysosomal function, autophagic flux, and transcriptomic readouts
        stratified by causal allele and rescue status.
      biological_processes:
      - preferred_term: autophagy
        term:
          id: GO:0006914
          label: autophagy
      assays:
      - preferred_term: lysosomal function assay
      - preferred_term: single-cell transcriptomic profiling
      direction: NEGATIVE
    - name: Dopaminergic neuron survival and identity
      target: pathophysiology#Dopaminergic Neuron Loss
      description: >
        Cell survival, dopaminergic identity, and dopamine biosynthesis readouts
        after differentiation.
      biological_processes:
      - preferred_term: dopamine biosynthetic process
        term:
          id: GO:0042416
          label: dopamine biosynthetic process
      assays:
      - preferred_term: high-content imaging
      - preferred_term: targeted transcriptomic profiling
      direction: NEGATIVE
    controls:
    - name: Isogenic unedited parental hPSC line
      description: Same genetic background without Parkinson-associated edits.
    - name: Corrected rescue alleles
      description: Reciprocal correction of disease alleles where editing design allows.
    decision_criterion: >-
      A mechanism is prioritized when multiple independently edited clones for
      the same variant show a reproducible phenotype that is attenuated by
      isogenic correction and maps to a declared pathophysiology node.
    would_support:
    - pathophysiology#Alpha-Synuclein Aggregation
    - pathophysiology#Mitochondrial Dysfunction
    - pathophysiology#Autophagy-Lysosome Pathway Dysfunction
    - pathophysiology#Dopaminergic Neuron Loss
    would_refute:
    - pathophysiology#Alpha-Synuclein Aggregation
    - pathophysiology#Mitochondrial Dysfunction
    - pathophysiology#Autophagy-Lysosome Pathway Dysfunction
    evidence:
    - reference: PMID:38405931
      reference_title: "iSCORE-PD: an isogenic stem cell collection to research Parkinson's Disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "we generated a collection of 65 human stem cell lines genetically engineered to harbor high risk or causal variants in genes associated with PD"
      explanation: >-
        Demonstrates the feasibility of a large isogenic hPSC Parkinson variant
        collection for mechanism-resolved experiments.
    - reference: PMID:38405931
      reference_title: "iSCORE-PD: an isogenic stem cell collection to research Parkinson's Disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "rigorous quality controls, including whole-genome sequencing of each line."
      explanation: Supports WGS-QC as a design requirement for the proposed panel.
    - reference: PMID:36069759
      reference_title: "Highly efficient generation of isogenic pluripotent stem cell models using prime editing."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Finally, we demonstrated that this mRNA-based delivery approach can be used repeatedly to yield editing efficiencies exceeding 60% and to correct or introduce familial mutations causing Parkinson's disease in hPSCs."
      explanation: >-
        Supports prime editing as a practical modality for generating and
        correcting Parkinson disease mutations in hPSCs.
  evidence:
  - reference: PMID:38405931
    reference_title: "iSCORE-PD: an isogenic stem cell collection to research Parkinson's Disease."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Our iSCORE-PD collection represents an easily accessible and valuable platform to study PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting."
    explanation: >-
      Establishes the existence of a human isogenic hPSC resource for studying
      Parkinson molecular pathophysiology, while the specific knowledge gap
      remains the standardized phenotype-to-mechanism adjudication.
- discussion_id: gap_pd_weight_loss_multifactorial_mechanisms
  prompt: >-
    Weight loss is a long-observed non-motor symptom of Parkinson disease, yet
    its mechanisms remain incompletely understood. Which of the proposed pathways
    — metabolic dysregulation, neuroendocrine disruption, gastrointestinal
    dysfunction, cognitive decline, and pharmacologic effects — are primary drivers
    versus secondary consequences, and how do they interact across the disease course?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Dopaminergic Neuron Loss
  - pathophysiology#Intestinal Inflammation and Barrier Dysfunction
  - pathophysiology#Basal Ganglia Circuit Dysfunction
  rationale: >-
    Weight loss exerts substantial morbidity and mortality in PD, yet limited
    mechanistic understanding constrains treatment options. The Gabriel et al.
    (2026) review identifies six interacting pathways: (1) metabolic
    dysregulation (altered energy expenditure or intake), (2) neuroendocrine
    disruption (leptin/ghrelin/GLP-1 signaling), (3) gastrointestinal
    dysfunction (dysmotility, malabsorption, barrier dysfunction), (4) cognitive
    decline (reduced appetite awareness), (5) dopaminergic-medication effects
    (appetite suppression), and (6) brain stimulation paradoxes (DBS-induced
    weight changes). The relative contribution and temporal ordering of these
    mechanisms remain unknown. Resolving cross-mechanism interactions would
    enable targeted metabolic interventions in PD.
  proposed_experiments:
  - experiment_id: exp_pd_weight_loss_longitudinal_mechanisms
    name: Longitudinal weight loss phenotype stratification with multi-mechanism readouts
    description: >-
      Follow a large PD cohort with serial body composition (DXA, bioimpedance),
      resting metabolic rate, circulating metabolic hormones (leptin, adiponectin,
      GLP-1, ghrelin), dopamine-agonist doses and appetite-affecting medications,
      cognitive testing, gastrointestinal symptom questionnaires, and GI transit
      imaging. Stratify the cohort into weight-loss phenotypes (progressive vs.
      stable) and identify mechanistic signatures.
    experiment_type:
      preferred_term: longitudinal multi-omics observational cohort study
    readouts:
    - name: Metabolic rate and body composition trajectories
      target: pathophysiology#Dopaminergic Neuron Loss
      description: >
        Measure resting metabolic rate, energy expenditure, and changes in
        lean vs. fat mass to distinguish metabolic dysregulation from
        reduced intake.
      assays:
      - preferred_term: indirect calorimetry
      - preferred_term: dual-energy X-ray absorptiometry
      direction: NEGATIVE
    - name: Circulating neuroendocrine hormone patterns
      target: pathophysiology#Dopaminergic Neuron Loss
      description: >
        Quantify leptin, ghrelin, adiponectin, GLP-1, and other appetite-
        regulating hormones to identify dysregulation of satiety/hunger signaling.
      assays:
      - preferred_term: serum hormone quantification
      direction: NEGATIVE
    - name: Gastrointestinal function and symptoms
      target: pathophysiology#Intestinal Inflammation and Barrier Dysfunction
      description: >
        Assess gastric emptying (breath test), small-bowel transit, colonic
        function, permeability markers (zonulin, calprotectin), and GI symptom
        severity to establish causal vs. consequential GI involvement.
      assays:
      - preferred_term: gastric-emptying scintigraphy
      - preferred_term: fecal calprotectin assay
      direction: NEGATIVE
    - name: Cognitive decline severity
      target: pathophysiology#Basal Ganglia Circuit Dysfunction
      description: >
        Administer validated cognitive batteries (MoCA, MMSE) and assess
        appetite awareness to test the cognitive-suppression hypothesis.
      assays:
      - preferred_term: cognitive assessment battery
      direction: NEGATIVE
    decision_criterion: >-
      Mechanistic dominance is supported by: (1) trajectories preceding or
      independent of weight loss (dysmetabolism, hormone changes, GI dysfunction);
      (2) stratification of the cohort into mechanistically distinct weight-loss
      phenotypes; (3) reproducible associations between mechanism-specific markers
      and subsequent weight-loss progression in converters.
    would_support:
    - pathophysiology#Dopaminergic Neuron Loss
    - pathophysiology#Intestinal Inflammation and Barrier Dysfunction
    - pathophysiology#Basal Ganglia Circuit Dysfunction
  evidence:
  - reference: PMID:41781031
    reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "weight loss has long been observed in PD and other neurodegenerative disorders, yet the mechanisms remain incompletely understood. This limited mechanistic insight has left few treatment options for weight loss in PD."
    explanation: >-
      The Gabriel et al. review establishes weight loss as a significant yet
      mechanistically unexplained PD symptom, directly motivating this knowledge gap.
  - reference: PMID:41781031
    reference_title: "When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Emerging research highlights the role of metabolic regulation, neuroendocrine signaling, pharmacologic treatment, cognitive decline, gastrointestinal dysfunction, and brain stimulation in shaping weight trajectories in PD."
    explanation: >-
      This enumerates the six candidate mechanisms for weight loss in PD,
      supporting the multi-pathway framing of the gap.

computational_models:
- name: Alpha-Synuclein Aggregation BST Model
  description: >
    Biochemical Systems Theory (BST) model of alpha-synuclein aggregation kinetics
    in dopaminergic neurons. Integrates dopamine metabolism, ubiquitin-proteasome
    system, and lysosomal degradation pathways. Simulates effects of oxidative
    stress and proteasome inhibition on synuclein accumulation.
  modeled_mechanisms:
  - target: Alpha-Synuclein Aggregation
    description: Models alpha-synuclein aggregation kinetics and degradation-pathway effects in dopaminergic neurons.
  model_type: KINETIC
  repository_url: https://www.ebi.ac.uk/biomodels/BIOMD0000000575
  model_id: BIOMD0000000575
  publication: PMID:19136028
  notes: First comprehensive kinetic model of PD-related protein aggregation
- name: Whole Dopaminergic Neuron SBML Model
  description: >
    Large-scale Systems Biology Markup Language (SBML) model of dopaminergic
    neuron containing 139 reactions and 111 metabolites. Captures dopamine
    synthesis, vesicular storage, release, reuptake, and degradation alongside
    mitochondrial function and oxidative stress.
  modeled_mechanisms:
  - target: Striatal Dopamine Deficiency
    description: Models dopamine synthesis, storage, release, reuptake, and degradation in dopaminergic-neuron physiology.
  - target: Mitochondrial Dysfunction
    description: Models mitochondrial metabolism alongside dopamine handling in dopaminergic neurons.
  model_type: KINETIC
  repository_url: https://www.ebi.ac.uk/biomodels/MODEL1302200000
  model_id: MODEL1302200000
  publication: PMID:24196439
  model_format: SBML
  notes: Enables simulation of drug effects on dopaminergic neurotransmission
- name: Basal Ganglia Spiking Neural Network
  description: >
    Computational model of the basal ganglia circuit capturing dopamine-modulated
    dynamics between striatum, globus pallidus, subthalamic nucleus, and
    substantia nigra. Simulates pathological beta-band oscillations and motor
    dysfunction in PD.
  modeled_mechanisms:
  - target: Basal Ganglia Circuit Dysfunction
    description: Models dopamine-modulated basal ganglia circuit dynamics, beta-band oscillations, and DBS effects.
  model_type: PHYSIOLOGICAL
  publication: PMID:29666208
  notes: Models circuit-level effects of dopamine depletion and DBS therapy
- name: Alpha-Synuclein Prion-like Spreading Model
  description: >
    Network diffusion model simulating prion-like propagation of misfolded
    alpha-synuclein through brain connectome. Uses graph-theoretical approach
    to predict spatial patterns of neurodegeneration from initial seeding sites.
  modeled_mechanisms:
  - target: Alpha-Synuclein Aggregation
    description: Models connectome-based propagation of misfolded alpha-synuclein pathology.
  model_type: AGENT_BASED
  notes: Predicts Braak staging patterns from connectivity-based spreading
references:
- reference: DOI:10.2147/ndt.s540718
  title: Updates on Parkinson’s Disease
  findings: []
- reference: DOI:10.3389/fnagi.2025.1617106
  title: 'Understanding Parkinson’s disease: current trends and its multifaceted complications'
  findings: []
- reference: DOI:10.3390/cells14151161
  title: 'Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation'
  findings: []
- reference: DOI:10.3390/ijms25137183
  title: 'A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects'
  findings: []

📚

References & Deep Research

References

DOI:10.2147/ndt.s540718

Updates on Parkinson’s Disease

No top-level findings curated for this source.

DOI:10.3389/fnagi.2025.1617106

Understanding Parkinson’s disease: current trends and its multifaceted complications

No top-level findings curated for this source.

DOI:10.3390/cells14151161

Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation

No top-level findings curated for this source.

DOI:10.3390/ijms25137183

A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects

No top-level findings curated for this source.

Deep Research

Disorder ▸

Disorder

Name: Parkinson's Disease
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 67

Key Pathophysiology Nodes

Dopaminergic Neuron Loss
Alpha-Synuclein Aggregation
Mitochondrial Dysfunction
Neuroinflammation
Autophagy-Lysosome Pathway Dysfunction
Gut-Brain Axis Dysfunction
Oxidative Stress
Calcium Dysregulation
Endoplasmic Reticulum Stress
Synaptic Dysfunction
Iron Accumulation and Ferroptosis
Blood-Brain Barrier Dysfunction

Citation Inventory (for evidence mapping)

DOI:10.1016/s0140-6736(23
DOI:10.2147/ndt.s540718
DOI:10.3389/fnagi.2025.1617106
DOI:10.3390/cells14151161
DOI:10.3390/ijms25137183

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 15 citations 2025-12-17T18:36:16.429486

Disease Pathophysiology Research Report

Target Disease - Disease Name: Parkinson’s disease (PD) - MONDO ID: MONDO:0005180 - Category: Complex

1) Core Pathophysiology: current understanding - Alpha‑synuclein misfolding, aggregation, and propagation: PD pathogenesis centers on abnormal alpha‑synuclein (SNCA) aggregation into Lewy bodies/neurites with prion‑like spread across neural networks. Evidence integrates genetics (SNCA dosage/mutations), neuropathology (Lewy inclusions capturing mitochondria/lysosomes), and in vivo propagation models. As a recent authoritative review states: “abnormal alpha‑synuclein aggregation and spreading between gut, brainstem and higher brain regions [is] a likely substrate for disease initiation and progression,” with oligomers likely more toxic than large aggregates (The Lancet, Jan 2024; doi:10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4). See also (morris2024thepathogenesisof pages 4-7, bai2025updatesonparkinson’s pages 7-8). - Mitochondrial dysfunction and mitophagy failure: Fundamental mitochondrial deficits (complex I impairment, ROS, ATP shortfall) occur early, interlinked with PINK1/Parkin mitophagy pathways; environmental complex I inhibitors (e.g., MPTP/pesticides) converge on this axis (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Lysosomal/autophagy and endo‑lysosomal trafficking defects: Genetics and pathway data implicate lysosomal pathways (e.g., GBA1, LRRK2, VPS35), with impaired proteostasis driving alpha‑syn accumulation (Lancet 2024; 2024 IJMS review) (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4). - Neuroinflammation and glial crosstalk: Chronic microglial/astrocytic activation, cytokine cascades, and gut–brain immune signaling likely contribute to progression; immune‑inflammatory mechanisms are highlighted as key but incompletely resolved (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Calcium homeostasis, synaptic and axonal dysfunction: Early synaptic injury (vesicle trafficking, axonal transport) and calcium dysregulation precede neuronal loss, particularly in vulnerable nigrostriatal dopaminergic neurons (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Body‑first vs brain‑first and gut–brain axis: Both Braak’s peripheral‑to‑central model and a “brain‑first” trajectory are supported; prodromal autonomic/GI features and RBD support a body‑first subtype in a substantial subgroup (Lancet 2024; 2025 narrative synthesis) (morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7, chaudhary2025understandingparkinson’sdisease pages 2-3).

2) Key Molecular Players - Genes/Proteins (HGNC): - SNCA (alpha‑synuclein): causal; mutations/dosage increase aggregation and drive aggressive phenotypes (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - LRRK2 (PARK8): most common Mendelian PD; kinase activity implicated; variants (e.g., G2019S, R1441) and downstream lysosomal/endolysosomal effects (Lancet 2024; IJMS 2024) (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4). - PRKN (Parkin; PARK2), PINK1 (PARK6): recessive; central to mitophagy, mitochondrial quality control (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - PARK7 (DJ‑1): recessive; oxidative stress responses (IJMS 2024) (alvarez2024acomprehensiveapproach pages 2-4). - GBA1 (glucocerebrosidase): strongest risk factor among lysosomal enzyme genes; glucosylceramide handling, autophagy‑lysosomal pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - VPS35: endosomal trafficking; links to lysosome/autophagy (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Polygenic risk: “90 independent variants across 74 genomic loci” implicating lysosome–autophagy and immune pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Chemical entities (CHEBI) and modulators: - Dopamine (CHEBI:18243): neurotransmitter depleted in striatum; levodopa remains pivotal symptomatic therapy (IJMS 2024) (alvarez2024acomprehensiveapproach pages 2-4). - Glucosylceramide (CHEBI:18238): substrate in GBA1 pathway; links lipid metabolism to alpha‑syn burden (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Alpha‑synuclein‑targeting biologics and small molecules: therapeutic development ongoing (NDT 2025) (bai2025updatesonparkinson’s pages 1-2). - LRRK2 kinase inhibitors: BBB‑penetrant candidates entering clinical testing (NDT 2025) (bai2025updatesonparkinson’s pages 1-2). - Cell types (CL): - Midbrain dopaminergic neuron, substantia nigra pars compacta (CL:0002609): selectively vulnerable (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Microglia (CL:0000129) and astrocytes (CL:0000127): drivers and modulators of neuroinflammation (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Enteric neurons/glia (ENS): peripheral initiation sites in body‑first subtype (Lancet 2024) (morris2024thepathogenesisof pages 1-4). - Anatomical locations (UBERON): - Substantia nigra pars compacta (UBERON:0002038), striatum (UBERON:0002435): canonical motor circuit pathology (Lancet 2024) (morris2024thepathogenesisof pages 4-7). - Olfactory bulb (UBERON:0002312); dorsal motor nucleus of vagus (UBERON:0002826); enteric nervous system (UBERON:0007250): prodromal/peripheral staging nodes (Lancet 2024) (morris2024thepathogenesisof pages 1-4).

3) Biological Processes (GO) disrupted - Protein aggregation and amyloid fibril formation; synaptic vesicle cycle; axonal transport; calcium ion homeostasis (GO:0006816); oxidative phosphorylation and response to oxidative stress (GO:0006979); mitophagy (GO:0000423) and mitochondrial fission/fusion; autophagy (GO:0006914) and lysosomal organization; innate immune signaling and microglial activation. Mechanistic reviews emphasize mitochondria–ER–lysosome network disruption, with alpha‑syn propagating pathology across these systems (Lancet 2024; Cells 2025) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7).

4) Cellular Components (GOCC) - Presynaptic terminals (alpha‑syn physiology/pathology), Lewy bodies/neurites (cytoplasmic inclusions capturing organelles), mitochondria, lysosomes, endosomes, ER, synaptic vesicles. Lewy bodies “trap organelles including mitochondria and lysosomes,” linking aggregation to organellar dysfunction (Lancet 2024, Jan 2024; doi link below) (morris2024thepathogenesisof pages 4-7).

5) Disease Progression and Staging - Sequence of events: prodrome → early synaptic/metabolic stress → alpha‑syn oligomer accumulation and fibril formation → organellar (mitochondria/lysosome) stress and impaired mitophagy → neuroinflammation/glial activation → progressive nigrostriatal degeneration and network spread → clinical motor syndrome and expanding non‑motor burden (Lancet 2024) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Braak staging and heterogeneity: classical six‑stage model proposes initial lesions in olfactory bulb/ENS with ascending spread; however, “many cases do not follow Braak staging,” and a brain‑first subtype also exists, underscoring divergent pathways (Lancet 2024) (morris2024thepathogenesisof pages 1-4). Body‑first vs brain‑first dichotomy and prodromal subtypes are emphasized in 2025 expert synthesis advocating biological definitions and prevention‑trial design (Cells 2025, Jul 2025; doi:10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7). - Prodromal markers: REM sleep behavior disorder (RBD), anosmia, constipation/autonomic dysfunction, subtle cognitive/affective changes are integrated into MDS criteria for prodromal PD (Lancet 2024) (morris2024thepathogenesisof pages 1-4).

6) Phenotypic Manifestations (HP terms) - Motor: bradykinesia (HP:0002067), rigidity (HP:0002063), resting tremor (HP:0002322), gait disturbance/postural instability (HP:0002066). These reflect nigrostriatal dopamine loss and basal ganglia circuit plasticity changes (Lancet 2024) (morris2024thepathogenesisof pages 4-7). - Non‑motor: hyposmia (HP:0004408), constipation (HP:0002019), orthostatic hypotension (HP:0001278), REM sleep behavior disorder (HP:0002362), depression/anxiety (HP:0000716/HP:0000739), cognitive impairment/dementia (HP:0100543/HP:0000726). These map to early involvement of olfactory, autonomic and limbic systems and widespread network pathology (Lancet 2024; Cells 2025) (morris2024thepathogenesisof pages 1-4, tanaka2025parkinson’sdiseasebridging pages 6-7).

7) Biomarkers and clinical tools (with URLs/dates) - Alpha‑synuclein seed amplification assays (SAA/RT‑QuIC): Biomarker panels now include α‑syn SAA from CSF or minimally invasive tissues; reviews highlight SAA’s high diagnostic performance in manifest/prodromal cohorts, while stressing standardization and access limitations. Notably, “alpha‑synuclein seed amplification assays…are being used clinically for biochemical diagnosis” in synucleinopathies, although broader deployment requires harmonization (published 2025/2024 syntheses) (NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718; Lancet 2024, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (bai2025updatesonparkinson’s pages 1-2, morris2024thepathogenesisof pages 1-4). A 2025 synthesis also emphasizes SAA utility within biomarker‑driven definitions and prevention trials (Cells 2025, Jul 2025, https://doi.org/10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7). - Imaging: Dopamine transporter (DAT) SPECT and advanced PET tracers delineate dopaminergic degeneration; neuromelanin and iron‑sensitive MRI support staging; multimodal imaging of inflammation and neurotransmitters is expanding for prodrome (Lancet 2024; NDT 2025) (https://doi.org/10.1016/S0140-6736(23)01478-2; https://doi.org/10.2147/ndt.s540718) (morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2). - Emerging alpha‑syn PET: First clinical alpha‑syn PET signals are reported in specific synucleinopathies and are anticipated to expand; timelines and challenges are discussed as part of a broader biomarker roadmap toward biological PD definitions (Cells 2025, Jul 2025) (tanaka2025parkinson’sdiseasebridging pages 6-7). - Digital biomarkers: Wearables and remote sensing aid motor/non‑motor phenotyping and may enrich trials; “digital phenotyping” can predict fluctuations and support early detection, though validation and equity are needed (NDT 2025, Sep 2025) (bai2025updatesonparkinson’s pages 1-2).

8) Current applications and real‑world implementations - Clinical practice: Combined use of clinical criteria (MDS), dopaminergic imaging when indicated, and selective application of fluid/tissue α‑syn SAA is growing in expert centers; expert reviews call for standardization and access expansion (Lancet 2024; NDT 2025) (morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2). - Trials and pipelines: Disease‑modifying strategies include α‑syn immunotherapies, lysosomal/mitophagy enhancers, and kinase modulators (e.g., LRRK2 inhibitors). Expert pipeline summaries highlight BBB‑penetrant LRRK2 inhibitors and α‑syn therapies progressing through phase II, with trial design evolving toward prodromal/biological staging (NDT 2025, Sep 2025; Cells 2025, Jul 2025) (bai2025updatesonparkinson’s pages 1-2, tanaka2025parkinson’sdiseasebridging pages 6-7). - Prevention framing: Given prodromal biomarkers (SAA, imaging, genetics), secondary prevention trials are advocated, with subtype‑specific enrichment (e.g., RBD cohorts, genetic carriers) (Cells 2025, Jul 2025) (tanaka2025parkinson’sdiseasebridging pages 6-7).

9) Expert opinions and analysis (authoritative sources, 2023–2025) - The Lancet 2024 review synthesizes genetics, organellar pathology, immune mechanisms, and heterogeneity, concluding: “There are currently no disease‑modifying treatments, but mechanistic insights… provide a basis for targeted neuroprotective strategies” (Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4). - Recent expert syntheses emphasize a shift to biological definitions integrating α‑syn SAA/imaging, genetics, and digital phenotyping, and call for prevention‑trial designs and equitable biomarker access (Cells 2025, Jul 2025, https://doi.org/10.3390/cells14151161; NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718) (tanaka2025parkinson’sdiseasebridging pages 6-7, bai2025updatesonparkinson’s pages 1-2).

10) Relevant statistics and recent epidemiology (2019–2024) - Global burden: PD affects “over ten million individuals” worldwide, with rising prevalence over the last decade and incidence typically 8–18 per 100,000 person‑years; male predominance ~1.5×; early‑onset PD 5–10% (NDT 2025, Sep 2025, https://doi.org/10.2147/ndt.s540718) (bai2025updatesonparkinson’s pages 1-2). Contemporary global analyses cited by these reviews corroborate increasing age‑standardized prevalence and regional heterogeneity (Lancet 2024, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4).

Structured Annotations for a Knowledge Base - Pathophysiology (summary): Aggregated α‑synuclein seeds propagate across neural/peripheral networks, impairing synapses and organellar homeostasis (mitochondria–lysosome–ER). Mitophagy failure (PINK1/PRKN) and lysosomal dysfunction (GBA1, LRRK2, VPS35) amplify proteostasis stress and neuroinflammation, culminating in nigrostriatal degeneration and widespread network involvement (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - Gene/Protein annotations (HGNC): SNCA; LRRK2; PRKN; PINK1; PARK7; GBA; VPS35 (morris2024thepathogenesisof pages 1-4, alvarez2024acomprehensiveapproach pages 2-4). - GO Biological Processes: mitophagy (GO:0000423); autophagy (GO:0006914); synaptic vesicle cycle (GO:0099504); axonal transport (GO:0098930); calcium ion homeostasis (GO:0006874); response to oxidative stress (GO:0006979); innate immune response (GO:0045087) (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4). - GO Cellular Components: presynapse (GO:0098793); mitochondrion (GO:0005739); lysosome (GO:0005764); endosome (GO:0005768); Lewy body (GO:0097418) (morris2024thepathogenesisof pages 4-7). - Cell Types (CL): dopaminergic neuron, SNpc (CL:0002609); microglial cell (CL:0000129); astrocyte (CL:0000127); enteric neuron (CL:0000700) (morris2024thepathogenesisof pages 1-4). - Anatomy (UBERON): substantia nigra pars compacta (UBERON:0002038); striatum (UBERON:0002435); olfactory bulb (UBERON:0002312); dorsal motor nucleus of vagus (UBERON:0002826); enteric nervous system (UBERON:0007250) (morris2024thepathogenesisof pages 1-4). - Chemical Entities (CHEBI): dopamine (CHEBI:18243); glucosylceramide (CHEBI:18238); representative therapeutic classes: LRRK2 kinase inhibitors; α‑synuclein immunotherapies (bai2025updatesonparkinson’s pages 1-2, morris2024thepathogenesisof pages 1-4).

Direct supporting statements (quotes) - “Abnormal alpha‑synuclein aggregation and spreading between gut, brainstem and higher brain regions [is] a likely substrate for disease initiation and progression.” (The Lancet, Jan 2024, https://doi.org/10.1016/S0140-6736(23)01478-2) (morris2024thepathogenesisof pages 1-4) - “Cellular mechanisms implicated across monogenic and sporadic PD include mitochondrial, lysosomal and endosomal dysfunction, and maladaptive immune/inflammatory responses.” (The Lancet, Jan 2024, ibid.) (morris2024thepathogenesisof pages 1-4) - “There are currently no disease‑modifying treatments, but mechanistic insights… provide a basis for targeted neuroprotective strategies.” (The Lancet, Jan 2024, ibid.) (morris2024thepathogenesisof pages 1-4) - Reviews from 2025 emphasize a biomarker‑based, prevention‑trial framework: “biological definition… integrating in vivo detection of neuronal α‑synuclein aggregation, neurodegeneration and genetics” (Cells, Jul 2025, https://doi.org/10.3390/cells14151161) (tanaka2025parkinson’sdiseasebridging pages 6-7).

Notes on scope and limitations - GLP‑1 receptor agonists and other metabolic approaches are active areas, but detailed clinical meta‑analyses were not directly quoted in the evidence items here; we therefore limited claims to pipeline‑level commentary in authoritative reviews (bai2025updatesonparkinson’s pages 1-2). For detailed efficacy estimates, consult recent trial/meta‑analytic papers.

References (with links and dates) - Morris HR, Spillantini MG, Sue CM, Williams‑Gray CH. The pathogenesis of Parkinson’s disease. The Lancet. 2024 Jan;403:293–304. doi:10.1016/S0140-6736(23)01478-2. https://doi.org/10.1016/S0140-6736(23)01478-2 (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4) - Bai H, Ma W, Zhu L, et al. Updates on Parkinson’s Disease. Neuropsychiatric Disease and Treatment. 2025 Sep;21:1945–1953. doi:10.2147/ndt.s540718. https://doi.org/10.2147/ndt.s540718 (bai2025updatesonparkinson’s pages 1-2, bai2025updatesonparkinson’s pages 7-8) - Tanaka M. Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation. Cells. 2025 Jul;14:1161. doi:10.3390/cells14151161. https://doi.org/10.3390/cells14151161 (tanaka2025parkinson’sdiseasebridging pages 6-7, tanaka2025parkinson’sdiseasebridging pages 2-4) - Álvarez MM, Cano‑Herrera G, Osorio Martínez MF, et al. A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects. International Journal of Molecular Sciences. 2024 Jun;25:7183. doi:10.3390/ijms25137183. https://doi.org/10.3390/ijms25137183 (alvarez2024acomprehensiveapproach pages 2-4)

Overall synthesis: Contemporary consensus places alpha‑synuclein aggregation/propagation at the core of PD, intersecting with mitochondrial and lysosomal/autophagy dysfunction and immune signaling to produce early synaptic failure and progressive network neurodegeneration. Heterogeneous trajectories (brain‑first, body‑first) map to prodromal markers and likely subtypes. Biomarker advances—especially α‑syn SAA, dopaminergic imaging, and emerging α‑syn PET—support a shift toward biologically defined diagnosis and prevention‑trial designs, while pipelines target α‑syn, LRRK2, lysosome and mitophagy for disease modification. The global burden continues to rise with aging populations, underscoring the urgency of biomarker‑driven, mechanistically informed interventions (morris2024thepathogenesisof pages 4-7, morris2024thepathogenesisof pages 1-4, bai2025updatesonparkinson’s pages 1-2).

References

(morris2024thepathogenesisof pages 1-4): Huw R Morris, Maria Grazia Spillantini, Carolyn M Sue, and Caroline H Williams-Gray. The pathogenesis of parkinson's disease. The Lancet, 403:293-304, Jan 2024. URL: https://doi.org/10.1016/s0140-6736(23)01478-2, doi:10.1016/s0140-6736(23)01478-2. This article has 739 citations and is from a highest quality peer-reviewed journal.
(morris2024thepathogenesisof pages 4-7): Huw R Morris, Maria Grazia Spillantini, Carolyn M Sue, and Caroline H Williams-Gray. The pathogenesis of parkinson's disease. The Lancet, 403:293-304, Jan 2024. URL: https://doi.org/10.1016/s0140-6736(23)01478-2, doi:10.1016/s0140-6736(23)01478-2. This article has 739 citations and is from a highest quality peer-reviewed journal.
(bai2025updatesonparkinson’s pages 7-8): Hong Bai, Wenhui Ma, Lei Zhu, Yaling Lu, Jiaojiao Fan, Mengjia Chen, and Cong Huang. Updates on parkinson’s disease. Neuropsychiatric Disease and Treatment, Volume 21:1945-1953, Sep 2025. URL: https://doi.org/10.2147/ndt.s540718, doi:10.2147/ndt.s540718. This article has 1 citations and is from a peer-reviewed journal.
(alvarez2024acomprehensiveapproach pages 2-4): Mauricio Muleiro Alvarez, Gabriela Cano-Herrera, María Fernanda Osorio Martínez, Joaquin Vega Gonzales-Portillo, Germán Rivera Monroy, Renata Murguiondo Pérez, Jorge Alejandro Torres-Ríos, Ximena A. van Tienhoven, Ernesto Marcelo Garibaldi Bernot, Felipe Esparza Salazar, and Antonio Ibarra. A comprehensive approach to parkinson’s disease: addressing its molecular, clinical, and therapeutic aspects. International Journal of Molecular Sciences, 25:7183, Jun 2024. URL: https://doi.org/10.3390/ijms25137183, doi:10.3390/ijms25137183. This article has 51 citations and is from a poor quality or predatory journal.
(tanaka2025parkinson’sdiseasebridging pages 6-7): Masaru Tanaka. Parkinson’s disease: bridging gaps, building biomarkers, and reimagining clinical translation. Cells, 14:1161, Jul 2025. URL: https://doi.org/10.3390/cells14151161, doi:10.3390/cells14151161. This article has 16 citations and is from a poor quality or predatory journal.
(chaudhary2025understandingparkinson’sdisease pages 2-3): Sameer A. Chaudhary, Sapana Chaudhary, and Sakshi Rawat. Understanding parkinson’s disease: current trends and its multifaceted complications. Frontiers in Aging Neuroscience, Sep 2025. URL: https://doi.org/10.3389/fnagi.2025.1617106, doi:10.3389/fnagi.2025.1617106. This article has 1 citations and is from a peer-reviewed journal.
(bai2025updatesonparkinson’s pages 1-2): Hong Bai, Wenhui Ma, Lei Zhu, Yaling Lu, Jiaojiao Fan, Mengjia Chen, and Cong Huang. Updates on parkinson’s disease. Neuropsychiatric Disease and Treatment, Volume 21:1945-1953, Sep 2025. URL: https://doi.org/10.2147/ndt.s540718, doi:10.2147/ndt.s540718. This article has 1 citations and is from a peer-reviewed journal.
(tanaka2025parkinson’sdiseasebridging pages 2-4): Masaru Tanaka. Parkinson’s disease: bridging gaps, building biomarkers, and reimagining clinical translation. Cells, 14:1161, Jul 2025. URL: https://doi.org/10.3390/cells14151161, doi:10.3390/cells14151161. This article has 16 citations and is from a poor quality or predatory journal.

Ask OpenScientist

OpenScientist Report

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Related Datasets

Computational Models

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)